Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4787 companies, A–Z).
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Spruce Biosciences reported a third-quarter 2026 net loss of $24.0 million, or $(8.51) per share, up from $8.2 million, or $(14.58) per share, a year earlier. The company also separated its CRHX-101 program into a new subsidiary, Adrenyx Biosciences, and plans to distribute Adrenyx shares to Spruce stockholders, a step its board has not yet approved.
Q3 2026 net loss was $24.0 million, or $(8.51) per share, versus $8.2 million, or $(14.58) per share, in Q3 2025; R&D expenses were $18.1 million.
Cash and cash equivalents were $87.7 million at September 30, 2026, up from $48.9 million at December 31, 2025, which the company says will fund operations and debt obligations into the second half of 2027.
The Distribution of Adrenyx stock is expected in the first half of 2027, but Spruce's board has not yet approved it or set a record date.
Under an amended Avenue loan agreement dated November 6, 2026, up to $15.0 million of Tranche 2 may be drawn between January 1, 2027 and March 31, 2027.
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million, up from $17.7 million a year earlier, as research and development expenses rose to $18.1 million from $14.3 million. The company reported no revenue in the quarter and said its cash, cash equivalents and short-term investments of $169.7 million should fund operations into the second half of 2028.
Q3 2026 net loss was $21.2 million, compared with $17.7 million in Q3 2025.
Research and development expenses were $18.1 million, compared with $14.3 million a year earlier.
Cash, cash equivalents and short-term investments were $169.7 million as of September 30, 2026, versus $145.7 million at December 31, 2025.
The Phase 1 trial of HWK-206 began in the U.S., and the FDA granted it Fast Track designation; initial Phase 1 data from HWK-007 and HWK-016 are expected in the first half of 2027.
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, up from $14.3 million, or $0.08 per share, a year earlier. Higher research and development and general and administrative spending drove the increase, and cash and marketable securities fell to $163 million, which the company says will fund operations into 2028.
Q3 2026 net loss was $27.2 million ($0.15 per share) versus $14.3 million ($0.08 per share) in Q3 2025.
Nine-month net loss was $70.6 million ($0.38 per share) versus $50.8 million ($0.34 per share) a year earlier.
Cash and marketable securities were $163 million at September 30, 2026, down from $209 million at December 31, 2025, with $48 million used in operating activities.
Bicara Therapeutics reported a third-quarter 2026 net loss of $71.2 million, nearly double the $36.3 million loss a year earlier, as research and development and general and administrative costs rose for its pivotal trial and commercial preparation. The company said its $442.3 million in cash and marketable securities should fund operations into the first half of 2029, and it reiterated that topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Net loss was $71.2 million for the quarter ended September 30, 2026, versus $36.3 million a year earlier.
Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses rose to $19.2 million from $7.7 million.
Cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, which the company expects to fund operations into the first half of 2029.
Topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Popular, Inc. filed an 8-K updating its third-quarter 2026 results after a commercial borrower in the quick service restaurant industry substantially ceased operations and filed for Chapter 11 bankruptcy following the earnings release. The company recognized an additional $38 million provision for credit losses, lowering quarterly net income to $242.4 million from $266.3 million and diluted EPS to $3.83 from $4.21, and it raised its 2026 net charge-off guidance to 90 bps to 95 bps from 80 bps to 90 bps.
Q3 2026 net income of $242.4 million, down $23.9 million from the $266.3 million in the original earnings release.
Diluted EPS of $3.83 versus $4.21 as originally issued; up from $3.14 in the same quarter of 2025.
The company expects an additional fourth-quarter 2026 charge-off on the same relationship.
2026 net charge-off guidance raised to 90 bps to 95 bps from 80 bps to 90 bps; Common Equity Tier 1 ratio of 16.01%, down 5 bps.
Tango Therapeutics reported a third quarter 2026 net loss of $68.4 million, or $0.39 per share, compared with net income of $15.9 million, or $0.13 per diluted share, in the same quarter of 2025. Collaboration revenue fell to $0 from $53.8 million after the Gilead collaboration concluded research activities in August 2025, while research and development and general and administrative spending both rose.
Collaboration revenue was $0 in Q3 2026, versus $53.8 million in Q3 2025.
R&D expenses rose to $48.9 million from $30.8 million; G&A expenses rose to $29.2 million from $8.9 million.
Cash, cash equivalents and marketable securities totaled $977.5 million as of September 30, 2026.
Tango intends to initiate a Phase 3 study of vopimetostat plus daraxonrasib in front-line pancreatic cancer in the first half of 2027.
Ocular Therapeutix reported third quarter 2026 results with total net revenue of $12.9 million, down from $14.5 million a year earlier, and a net loss of $94.8 million, or $(0.42) per share, versus a net loss of $69.4 million, or $(0.38) per share, in the prior-year quarter. Research and development expenses rose to $74.8 million from $52.4 million, and the company said it had $530.6 million in cash as of September 30, 2026, with runway expected into 2028.
Net revenue was $12.9 million for Q3 2026, compared with $14.5 million for Q3 2025.
Net loss was $(94.8) million, or $(0.42) per share, versus $(69.4) million, or $(0.38) per share, a year earlier.
R&D expenses were $74.8 million versus $52.4 million, reflecting faster HELIOS-3 and SOL-X enrollment and higher headcount.
Cash and cash equivalents were $530.6 million as of September 30, 2026; the company expects this to support operations into 2028.
Aura Biosciences reported third quarter 2026 results, with a net loss of $32.1 million, up from $26.1 million a year earlier. The company said a $4.5 million restructuring charge, tied to its reorganization around its ocular oncology portfolio, contributed to higher general and administrative expenses, and it reiterated that its cash is expected to last into the first half of 2029.
Net loss of $32.1 million for the quarter ended September 30, 2026, versus $26.1 million a year earlier; loss per share was $0.29, versus $0.40.
General and administrative expenses rose to $10.3 million from $5.7 million, driven mainly by restructuring charges of approximately $4.5 million.
Research and development expenses rose to $24.7 million from $22.2 million, tied to the Phase 3 CoMpass trial.
Cash, cash equivalents and marketable securities totaled $297.2 million as of September 30, 2026.
Virtus Investment Partners reported third-quarter 2026 results for the period ended September 30, 2026, with GAAP revenue of $197.6 million, down 9% from a year earlier, and diluted EPS of $3.26 versus $4.65. Assets under management fell 16% year over year to $141.4 billion, with net outflows of $6.1 billion, which weighs on future fee revenue for shareholders.
GAAP diluted EPS was $3.26 versus $4.65 a year earlier and $6.68 in the prior quarter; adjusted diluted EPS was $5.86 versus $7.35 a year earlier.
Revenue was $197.6 million, down 9% from $216.4 million a year earlier and down 2% from $201.4 million in the prior quarter.
Ending assets under management were $141.4 billion, down from $169.3 billion a year earlier, with net outflows of $6.1 billion.
The company repurchased 64,666 shares for $10.0 million and raised its quarterly dividend 2% to $2.45 per share.
Ispire Technology reported results for the quarter ended September 30, 2026. Revenue fell 9.3% from a year earlier, mainly on lower European sales, and the net loss widened to $6.4 million from $3.3 million, largely due to $4.8 million of credit loss expense. Compared with the prior quarter, revenue rose 3.2% and the net loss narrowed, and adjusted EBITDA turned positive at $136,000.
Revenue was $27.5 million, down from $30.4 million a year earlier, and up 3.2% from $26.7 million in the prior quarter.
Net loss was $6.4 million, or $(0.11) per share, versus $3.3 million, or $(0.06) per share, a year earlier.
Credit loss expense rose to $4.8 million from $1.8 million; adjusted EBITDA was $136,000 versus $0.6 million a year earlier.
Gross margin was 16.2%, compared with 17.0% a year earlier and 6.3% in the prior quarter.
Turn Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $(0.21) per share, up from $1.9 million, or $(0.07) per share, a year earlier. The company said its $10.4 million in cash as of September 30, 2026 is expected to fund operations into the third quarter of 2027, which matters to shareholders given the higher loss and the need for further capital.
Q3 2026 net loss was $6.2 million, or $(0.21) per basic and diluted share, versus $1.9 million, or $(0.07), in Q3 2025
Net loss from change in fair value of derivative liability instrument was $3.3 million in the quarter, compared with none in the prior-year period
Cash and cash equivalents were $10.4 million at September 30, 2026, with operations expected to be funded into the third quarter of 2027
loanDepot reported a third-quarter 2026 net loss of $29 million, up from $7 million in the prior quarter, on total revenue of $307 million, down 9% from $337 million. Origination volume fell 12% sequentially to $7.05 billion, though it rose 8% from a year earlier, and the company said higher interest rates and a difficult housing market weighed on results.
Net loss of $29 million versus $7 million in Q2 2026; diluted loss per share of $0.08 versus $0.02
Adjusted EBITDA of $17 million, down from $20 million in Q2 2026
Sold $10 billion of Agency mortgage servicing rights; agreed to sell another $9 billion of Government MSRs, which closed in October
Repurchased $87 million of senior notes at an average 88% of par; company is pursuing financing alternatives to refinance or extend debt
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million, down from approximately $1.4 million a year earlier, which it attributed to lower reimbursement per CyPath Lung test and a slight decline in cases at its Precision Pathology Laboratory Services subsidiary. The net loss widened to approximately $5.3 million from $5.1 million, as the operating loss grew to approximately $3.5 million from $2.3 million, and cash fell to approximately $2.6 million at September 30, 2026, which matters to shareholders given the company's continuing losses.
Q3 2026 revenue was approximately $1.1 million versus approximately $1.4 million in Q3 2025; nine-month CyPath Lung testing revenue rose 79% to approximately $1.1 million.
Q3 net loss was approximately $5.3 million versus $5.1 million; loss from operations was approximately $3.5 million versus $2.3 million.
Cash and cash equivalents were approximately $2.6 million at September 30, 2026, down from $6.4 million at December 31, 2025; a financing after quarter-end generated approximately $4.0 million in gross proceeds.
Sidus Space's audit committee concluded that its audited 2024 and 2025 annual reports and its 2026 quarterly reports for March 31 and June 30 should no longer be relied upon. The company expects the restatements to increase net loss for 2024 and for the first half of 2026, decrease net loss for 2025, and reduce stockholders' equity in every affected period, and it expects to report material weaknesses in internal controls.
Restatement covers the 2024 and 2025 annual reports and the Q1 and Q2 2026 quarterly reports; the 2024 and 2025 10-Ks were filed March 31, 2025 and April 1, 2026.
Net loss expected to increase by about $12.5 million for 2024 and about $4.1 million for the six months ended June 30, 2026; net loss expected to decrease by about $5.5 million for 2025.
Total stockholders' equity expected to decrease by about $15.0 million as of June 30, 2026, compared with amounts originally reported.
Main cause is warrant classification: 3,409,946 warrants issued December 17, 2024 should have been recorded as liabilities; the company also cited a $4.0 million impairment on its LS-2 satellite.
Quoin Pharmaceuticals reported a net loss of $4.9 million for the quarter ended September 30, 2026, up from $3.9 million a year earlier, and a nine-month net loss of $15.2 million versus $11.5 million. The company said it had about $33.2 million in cash, cash equivalents and marketable securities at quarter end, and it highlighted positive interim Netherton Syndrome data and new regulatory designations. Shareholders see a wider loss alongside clinical and regulatory progress.
Q3 2026 net loss was approximately $4.9 million, compared with approximately $3.9 million in Q3 2025.
Nine-month 2026 net loss was approximately $15.2 million, compared with approximately $11.5 million for the same period in 2025.
Cash, cash equivalents and marketable securities were approximately $33.2 million as of September 30, 2026.
Up to $50.0 million private placement was announced August 28, 2026, with approximately $30.8 million in initial upfront funding.
FB Bancorp reported third-quarter 2026 net income of $466 thousand, down from $1.1 million a year earlier, as non-interest expenses rose and net interest margin fell to 4.30% from 4.65%. Nine-month net income was $515 thousand versus $2.7 million, including a $1.1 million loss from discontinued mortgage banking operations. Shareholders face lower earnings and a commercial loan of approximately $19.8 million now classified as substandard.
Q3 2026 net income was $466 thousand versus $1.1 million in Q3 2025; continuing operations EPS was $0.03 versus $0.06.
Nine-month 2026 net income was $515 thousand, including a $1.1 million loss from discontinued operations, versus $2.7 million a year earlier.
Non-interest expenses rose $390 thousand, or 3.33%, in Q3 2026 year over year, with $686 thousand of stock-based compensation.
A commercial loan with a principal balance of approximately $19.8 million was classified substandard after two co-borrower entities filed for Chapter 11 in June 2026; no specific allowance was recorded.
Entera Bio reported a third-quarter 2026 net loss of $15.6 million, or $0.11 per share, up from $3.2 million, or $0.07 per share, a year earlier. The company reported no revenue in either period, and the filing attributes the increase mainly to a $7.5 million non-cash fair value remeasurement of pre-funded warrants. Shareholders also got an update that the first clinical site for the EB613 Phase 3 osteoporosis study is expected to be activated in late 2026, with cash of $265.9 million as of September 30, 2026.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $3.2 million a year earlier.
The loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.
Research and development expenses rose to $4.9 million from $1.6 million, mainly for EB613 Phase 3 start-up and the OPKO collaboration.
Cash and cash equivalents were $265.9 million as of September 30, 2026, following a July 2026 private placement with gross proceeds of approximately $275.0 million.
Gogo reported third quarter 2026 revenue of $213.2 million, down 5% from a year earlier, and a net loss of $3.2 million, compared with a $1.9 million loss in the same period of 2025. The company reiterated its 2026 guidance and said it amended and extended its roughly $600 million Term Loan B to October 2030, with $75 million in principal repayments committed through 2027.
Total revenue of $213.2 million, down 5% year over year; Military/Government service revenue rose 36% to $37.2 million
Net loss of $3.2 million (diluted loss of $0.02 per share) versus a $1.9 million loss in Q3 2025; Adjusted EBITDA of $41.0 million, down 27%
2026 guidance reiterated: total revenue of $870 million to $895 million and Adjusted EBITDA of $175 million to $185 million
Term Loan B extended to October 2030, with $30 million to be repaid by December 31, 2026 and $20 million more by December 31, 2027
CG Oncology reported a third-quarter 2026 net loss of $56.9 million, or $(0.64) per share, up from $43.8 million, or $(0.57) per share, a year earlier. Total revenue was $1.6 million, down from $1.7 million, while research and development expenses rose to $39.2 million from $27.9 million. Cash, cash equivalents and marketable securities were $984.5 million at September 30, 2026, which the company expects will fund operations through 2029.
Net loss of $56.9 million, or $(0.64) per share, for the quarter ended September 30, 2026, versus $43.8 million, or $(0.57) per share, a year earlier
Total revenue of $1.6 million, compared with $1.7 million in the prior-year quarter
Research and development expenses of $39.2 million, up from $27.9 million, mainly due to higher clinical trial costs and headcount-related compensation
PIVOT-006 Phase 3 topline data expected November 2026; BLA completion for BCG-unresponsive NMIBC expected in Q4 2026
Tredegar reported a third-quarter 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, compared with net income of $7.1 million, or $0.20 per share, a year earlier. Management said results were not where it wants them to be, citing lower building and construction demand at Bonnell Aluminum and weaker Surface Protection demand at High Performance Films. The results are a sharp drop in profitability for shareholders, and the filing gives no updated full-year guidance.
Q3 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, vs. net income of $7.1 million, or $0.20 per share, in Q3 2025
Q3 2026 Consolidated EBITDA from ongoing operations of $4.1 million, vs. $18.1 million in Q3 2025
Aluminum Extrusions Q3 2026 EBITDA from ongoing operations of $2.5 million, vs. $16.8 million in Q3 2025; sales volume fell 11.6%
Net debt rose to $32.7 million at September 30, 2026, from $28.4 million at December 31, 2025
Protara Therapeutics reported third quarter 2026 results, with a net loss of $21.7 million, or $0.35 per share, compared with a net loss of $13.3 million, or $0.31 per share, a year earlier. Research and development expenses rose to $16.8 million from $9.6 million, and the company said cash, cash equivalents and marketable debt securities of $143.1 million should fund operations into 2028.
Q3 2026 net loss of $21.7 million ($0.35 per share) vs. $13.3 million ($0.31 per share) in Q3 2025
R&D expenses rose to $16.8 million from $9.6 million, mainly from higher clinical trial costs of $4.4 million
Cash and marketable debt securities totaled $143.1 million as of September 30, 2026
On November 4, 2026, the company agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million
TechTarget reported third-quarter 2026 revenue of $119.2 million, down 2.5% from a year earlier, and said it now expects full-year 2026 revenue to be modestly lower than 2025. Its net loss narrowed sharply from the prior year, which included large goodwill impairment charges, but Adjusted EBITDA fell and the company gave a full-year 2026 Adjusted EBITDA range of $80 million to $85 million.
Q3 2026 revenue was $119.2 million, versus $122.3 million in Q3 2025; nine-month revenue was $341.4 million, versus $346.1 million
Q3 2026 net loss was $18.2 million, versus $76.8 million in Q3 2025; Q3 Adjusted EBITDA was $18.6 million, versus $22.6 million
Full-year 2026 Adjusted EBITDA outlook is $80 million to $85 million, with full-year revenue expected to be modestly lower than 2025
Cash was $35.3 million at September 30, 2026, with $120.1 million drawn on a $250 million revolving credit facility
Telephone and Data Systems reported third quarter 2026 total operating revenues of $306.7 million, down from $308.5 million a year earlier, and net income attributable to TDS common shareholders of $29.6 million from continuing operations, compared with $40.2 million. The company lowered TDS Telecom's 2026 revenue, Adjusted OIBDA and Adjusted EBITDA guidance, raised its capital expenditure estimate, and its board approved an incremental $250 million share repurchase authorization.
Q3 2026 diluted EPS from continuing operations was $0.26, versus $0.33 in Q3 2025; total operating revenues were $306.7 million versus $308.5 million.
TDS Telecom 2026 revenue guidance was cut to $990 million to $1,010 million from $1,000 million to $1,025 million; Adjusted OIBDA guidance was cut to $280 million to $300 million from $300 million to $320 million.
TDS Telecom capital expenditure guidance was raised to approximately $750 million from $625 million to $675 million.
The board approved an incremental $250 million share repurchase authorization; TDS repurchased about 6 million shares in the quarter at an average price of $36.65.
Ziff Davis reported unaudited third quarter 2026 results, with revenue down 5.6% from a year earlier and a swing to an operating loss of $33.6 million, including a $29.6 million goodwill impairment. Adjusted diluted EPS was $1.39 versus $1.40 a year earlier, and the company repurchased $92.0 million of its shares during the quarter. The company will discuss the results on a call on November 6, 2026.
Revenue was $289.3 million versus $306.5 million in Q3 2025; adjusted EBITDA was $82.2 million versus $97.8 million.
Net loss from continuing operations was $28.7 million, or $0.85 per diluted share, compared with a loss of $16.0 million, or $0.39 per share, in Q3 2025.
Adjusted diluted EPS was $1.39 compared with $1.40 a year earlier.
Share repurchases totaled $92.0 million in Q3 2026 and approximately $265 million for the first three quarters of 2026.
Revelation Biosciences reported results for the three and nine months ended September 30, 2026, with no revenue line in the filing. The net loss grew from a year earlier, and cash fell from $10.7 million at December 31, 2025 to $9.1 million, which the company says will fund operations into the second quarter of 2027.
Net loss for the three months ended September 30, 2026 was $3.3 million, compared with $1.9 million a year earlier.
Net loss for the nine months ended September 30, 2026 was $9.6 million, compared with $6.4 million a year earlier.
Cash and cash equivalents were $9.1 million at September 30, 2026, versus $10.7 million at December 31, 2025; the company expects this to fund operations into the second quarter of 2027.
Net cash used for operating activities was $2.6 million for the third quarter of 2026, compared with $1.6 million in the same period of 2025.
Brighthouse Financial reported third quarter 2026 net income available to shareholders of $302 million, or $5.21 per diluted share, down from $453 million, or $7.89 per share, a year earlier. Adjusted earnings fell to $527 million, or $9.12 per share, from $970 million, or $16.87 per share, though the company said its annual actuarial review added $314 million of net favorable notable items. The company also said regulatory approvals for the pending $70.00 per share Aquarian Capital acquisition are not expected before the December 6, 2026 Outside Date, and the parties are discussing an extension.
Net income available to shareholders was $302 million, or $5.21 per diluted share, versus $453 million, or $7.89 per share, in the third quarter of 2025.
Adjusted earnings, less notable items, were $213 million, or $3.68 per diluted share, versus $261 million, or $4.54 per share, a year earlier.
Annuity sales were $2.4 billion, including $2.1 billion of Shield Level Annuities, with annuity sales down 12% quarter-over-quarter.
The merger agreement's Outside Date is December 6, 2026; the company and Aquarian Capital are discussing an extension, with no assurance of agreement.
Ready Capital reported a third-quarter 2026 GAAP net loss of $62.2 million, or $(0.40) per share, compared with a net loss of $16.7 million, or $(0.13) per share, a year earlier. Distributable loss was $(0.53) per share, and the company declared $0.01 per common share in dividends, down from $0.125 a year earlier, which matters to shareholders because it reflects weaker earnings and a much smaller dividend.
Q3 2026 GAAP loss per common share of $(0.40), versus $(0.13) in Q3 2025; nine-month loss per share of $(2.27)
Distributable loss per common share of $(0.53); before realized losses, $(0.21)
Dividends declared per common share of $0.01 in Q3 2026, versus $0.125 in Q3 2025
Book value of $6.44 per common share as of September 30, 2026; cash of $157 million and total leverage of 2.8x
PLAYSTUDIOS reported third-quarter 2026 revenue of $48.9 million, down from $57.6 million a year earlier, and a net loss of $11.0 million, up from $9.1 million. The company discontinued two products, Tetris Block Party and The Win Zone, and recorded $6.7 million in non-cash impairment charges plus a $9.2 million goodwill impairment. It is not providing formal financial guidance, which leaves shareholders without a forward outlook.
Q3 2026 revenue was $48.9 million versus $57.6 million in Q3 2025; direct-to-consumer revenue rose 108% to $16.0 million.
Net loss was $11.0 million versus $9.1 million; Consolidated AEBITDA rose to $10.0 million from $7.2 million.
Goodwill impairment of $9.2 million and a $6.7 million non-cash impairment charge tied to the discontinued products.
No formal financial guidance was provided; restructuring annualized savings range was raised to $37.0 million to $39.0 million, with $44.6 million left on the share repurchase authorization.
BRT Apartments reported a wider net loss for the third quarter ended September 30, 2026, with a loss of $0.23 per diluted share versus $0.14 a year earlier. Funds from operations (FFO) and adjusted FFO (AFFO) per diluted share also declined, to $0.26 and $0.31 from $0.28 and $0.36, and combined portfolio net operating income slipped to $15.1 million from $15.3 million. The company declared a $0.25 per share dividend for the quarter.
Net loss attributable to common stockholders was $3.955 million, or $0.23 per diluted share, for Q3 2026, versus $2.707 million, or $0.14, in Q3 2025.
FFO per diluted share was $0.26, down from $0.28; AFFO per diluted share was $0.31, down from $0.36.
Combined portfolio NOI was $15.1 million for Q3 2026 compared with $15.3 million a year earlier.
A $0.25 per share dividend was declared for the third quarter of 2026.
Nkarta reported third-quarter 2026 results, with a net loss of $33.3 million, or $0.45 per share, compared with a net loss of $21.7 million, or $0.29 per share, a year earlier. The company said its $216.0 million in cash, cash equivalents, restricted cash and investments as of September 30, 2026, is expected to fund operations into 2029. Higher research and development spending drove the larger loss, and shareholders face continued losses while the company's lead candidate is still in clinical trials.
Q3 2026 net loss of $33.3 million ($0.45 per share), up from $21.7 million ($0.29 per share) in Q3 2025
R&D expenses rose to $29.5 million from $20.2 million; G&A expenses fell to $6.3 million from $7.1 million
Cash and investments were $216.0 million on September 30, 2026, down from $295.1 million on December 31, 2025
Initial NKX019 clinical data to be presented at ACR Convergence 2026, with an oral presentation on November 8
Hyster-Yale posted supplemental historical financial data on its website on November 5, 2026, alongside its third quarter 2026 results, in an Exhibit 99 furnished under Items 2.02 and 7.01. The schedules show third quarter 2026 revenue of $827.4 million, down 15.5% from a year earlier, and an operating loss of $9.1 million compared with an operating profit of $2.3 million in the third quarter of 2025.
Q3 2026 revenue of $827.4 million, down 15.5% from $979.1 million in Q3 2025
Q3 2026 gross profit of $124.1 million, or 15.0% of revenue
Q3 2026 operating loss of $9.1 million vs. operating profit of $2.3 million in Q3 2025; net loss attributable to stockholders of $14.9 million vs. $2.3 million a year earlier
Q3 2026 restructuring charges of $1.5 million, all in the Americas segment
BioAge Labs reported third quarter 2026 results on November 5, 2026. Collaboration revenue fell to $0.3 million from $2.1 million, and the net loss widened to $33.5 million, or $0.73 per share, from $20.2 million, or $0.56 per share, a year earlier, mainly due to clinical trial costs for BGE-102. The company had about $352.3 million in cash, cash equivalents and marketable securities, which it says will fund operations through 2029.
Net loss was $33.5 million ($0.73 per share) for the quarter ended September 30, 2026, versus $20.2 million ($0.56 per share) a year earlier.
Research and development expenses rose to $30.2 million from $18.5 million, driven by a $13.2 million increase in BGE-102 direct costs tied to the QUELL-CV and QUELL-DME trials.
Collaboration revenue was $0.3 million, down from $2.1 million, mainly due to a $1.7 million cumulative catch-up adjustment tied to a September 2026 Novartis agreement amendment.
Cash, cash equivalents and marketable securities totaled about $352.3 million as of September 30, 2026; QUELL-CV topline data are expected in the fourth quarter of 2026.
eGain reported fiscal first-quarter 2027 results for the quarter ended September 30, 2026. Total revenue was $21.9 million, down 7% from a year earlier, though the company said it was above the high end of its guidance. GAAP net income fell to $1.6 million, or $0.06 per share, from $2.8 million, or $0.10 per share, and the company reiterated its full-year fiscal 2027 outlook.
Total revenue was $21.9 million, down 7% from $23.5 million a year earlier, and above the high end of company guidance.
GAAP net income was $1.6 million, or $0.06 per share, versus $2.8 million, or $0.10 per share, in Q1 fiscal 2026.
On October 30, 2026, the compensation committee approved fiscal 2026 variable cash pay at 85% of target, including $85,000 for CEO Ashutosh Roy.
Tectonic Therapeutic reported third-quarter 2026 results in an 8-K that furnished its press release. The net loss widened year over year, driven by higher research and development and general and administrative spending, while the company reported favorable Phase 1a safety and pharmacokinetic results for TX2100 and said cash should fund operations into Q1 2029.
Net loss of $21.3 million, or $1.08 per share, for the three months ended September 30, 2026, versus $19.0 million, or $1.02 per share, a year earlier.
Research and development expenses rose to $17.4 million from $16.9 million; general and administrative expenses rose to $6.0 million from $5.0 million.
Cash and cash equivalents were $234.7 million at September 30, 2026, down from $253.8 million at December 31, 2025.
Topline results from the APEX Phase 2 trial of TX45 in PH-HFpEF are expected by the end of January 2027.
Horizon Technology Finance reported third quarter 2026 net investment income of $12.3 million, or $0.19 per basic share, down from $14.0 million, or $0.32 per share, a year earlier. The company posted a net decrease in net assets from operations of $28.2 million, or $0.43 per share, compared with a net increase of $30.7 million in the prior-year quarter, and net asset value fell to $5.56 per share from $7.12 a year earlier.
Net investment income of $12.3 million ($0.19 per basic share) vs. $14.0 million ($0.32) in Q3 2025; total investment income was $24.1 million vs. $26.3 million.
Net decrease in net assets from operations of $28.2 million ($0.43 per share), including net unrealized depreciation on investments of $29.1 million.
Net asset value was $5.56 per share at September 30, 2026, vs. $7.12 at September 30, 2025 and $6.98 at December 31, 2025.
Board declared monthly distributions of $0.06 per share for January, February and March 2027, totaling $0.18 per share; Q3 distributions were $0.27 per share.
Xponential Fitness reported third quarter 2026 revenue of $62.3 million, down 21% from a year earlier, and adjusted EBITDA of $24.3 million, down 27%. The company cut its net new studio openings outlook to 124 to 130 from about 150 and narrowed its adjusted EBITDA range to $91.0 million to $94.0 million from $91.0 million to $97.0 million, which lowers the top end, while the Board continues a strategic review that may include a sale of the company.
Q3 2026 revenue was $62.3 million versus $78.8 million; net income was $4.9 million, or $0.10 per basic share, compared with a net loss of $6.7 million a year earlier.
Adjusted EBITDA was $24.3 million versus $33.5 million; North America same store sales decreased 7.5%.
2026 net new studio openings outlook is 124 to 130, versus previous guidance of approximately 150.
2026 adjusted EBITDA outlook narrowed to $91.0 million to $94.0 million from $91.0 million to $97.0 million; the strategic review, announced in April and supported by Jefferies, may result in a sale of the company.
Wheeler Real Estate Investment Trust reported a net loss attributable to common stockholders of $5.5 million for the three months ended September 30, 2026, and total revenue fell 2.8% year-over-year to $23.2 million. Management cited same-property NOI growth of 5.8%, higher occupancy and a $16.6 million reduction in Series B preferred liquidation value, but FFO was $(3.3) million compared with $18.1 million a year earlier, which matters for shareholders assessing the company's core operating earnings.
Net loss attributable to common stockholders of $5.5 million, or $(113.37) per share, for the three months ended September 30, 2026
Total revenue of $23.2 million, down 2.8% year-over-year, with 10 fewer centers than the prior year
FFO of $(3.3) million versus $18.1 million a year earlier; AFFO of $2.8 million versus $2.0 million
$6.8 million non-operating loss from changes in fair value of derivative liabilities; total debt of $471.2 million versus $482.8 million at year-end 2025
Assured Guaranty reported third quarter 2026 net income attributable to the company of $78 million, or $1.75 per diluted share, down from $105 million, or $2.18, a year earlier. Adjusted operating income also declined, to $86 million, or $1.94 per share, from $124 million, or $2.57, in third quarter 2025, so the headline profit measures fell year over year for shareholders.
Net income attributable to AGL was $78 million, or $1.75 per diluted share, versus $105 million, or $2.18, in third quarter 2025.
Adjusted operating income was $86 million, or $1.94 per share, versus $124 million, or $2.57, a year earlier.
Shareholders' equity per share fell to $122.91 at September 30, 2026 from $125.32 at December 31, 2025, while adjusted book value per share rose to $192.60 from $186.43.
Third quarter capital returned to shareholders was $27 million, including $10 million of share repurchases and $17 million of dividends.
Nu Skin reported third-quarter 2026 revenue of $311.0 million, down 14.6% from $364.2 million a year earlier, and a GAAP net loss of $0.7 million, or $(0.02) per diluted share, compared with net income of $17.1 million, or $0.34 per share. Excluding certain charges, third-quarter EPS was $0.10, and the company projects 2026 GAAP EPS of $(5.08) to $(4.98) on revenue of $1.26 billion to $1.29 billion, with the GAAP loss reflecting a $167.5 million valuation allowance on deferred tax assets.
Q3 2026 revenue was $311.0 million, down 14.6%, with an approximately 1.1% foreign-currency impact; the company said revenue came in within its guidance range.
Q3 GAAP operating margin was 1.6%, or 3.7% excluding certain charges, compared with 5.9% a year earlier.
Nine-month 2026 net loss was $248.7 million, or $(5.13) per diluted share, versus net income of $145.7 million a year earlier.
Q4 2026 revenue is projected at $310 million to $340 million, with GAAP EPS of $0.05 to $0.15; the company expects sequential growth in the fourth quarter.
vTv Therapeutics reported a third-quarter 2026 net loss attributable to shareholders of $11.6 million, or $0.94 per share, up from $8.7 million, or $1.08 per share, a year earlier, with no revenue in either quarter. Research and development and general and administrative expenses both rose, and cash fell to $77.2 million from $88.9 million at December 31, 2025, which the company says is sufficient to fund operations well through the Phase 3 CATT1 topline readout expected in mid 2027.
Q3 2026 net loss attributable to vTv shareholders was $11.6 million ($0.94 per share), compared with $8.7 million ($1.08 per share) in Q3 2025.
R&D expenses rose to $7.5 million from $7.0 million; G&A expenses rose to $4.9 million from $3.7 million.
Cash and cash equivalents were $77.2 million at September 30, 2026, versus $88.9 million at December 31, 2025.
Nine-month 2026 revenue was $36.8 million, compared with none in the prior-year period, per the statement of operations.
Cogent Biosciences reported third quarter 2026 results, with a net loss of $111.4 million compared with $80.9 million a year earlier. Higher general and administrative spending tied to commercial readiness for bezuclastinib drove most of the increase, and the filing reports no revenue line. The company said its $791.1 million cash balance is expected to fund operations into late 2028.
Net loss was $111.4 million for the quarter ended September 30, 2026, versus $80.9 million for the same period of 2025.
General and administrative expenses rose to $42.1 million from $14.4 million, mainly for commercial readiness ahead of a potential bezuclastinib launch.
Research and development expenses were $75.1 million, up from $69.0 million.
Cash, cash equivalents and marketable securities were $791.1 million as of September 30, 2026, versus $900.8 million at December 31, 2025 and $792.3 million at June 30, 2026.
Cable One reported third quarter 2026 revenue of $332.2 million, down 11.7% from a year earlier, and a net loss of $431.8 million, compared with net income of $86.5 million in the prior-year quarter. The loss reflects $412.1 million of non-cash asset impairments, and the filing says existing liquidity will be insufficient to repay debt maturing from November 2027 onward without financing or extensions, and that Chapter 11 relief may become necessary.
Revenue was $332.2 million versus $376.0 million; residential data revenue fell 10.3% and business data fell 6.7%.
Net loss was $431.8 million, or $(75.66) per diluted share, including $412.1 million of asset impairments.
Adjusted EBITDA was $159.8 million, down 20.8% from $201.9 million; operating cash flow was $92.6 million, down 40.8%.
Gross debt was $3.55 billion at September 30, 2026, and the filing cites debt maturities starting November 12, 2027 and a possible Chapter 11 filing if financing is not obtained.
Nelnet reported third-quarter 2026 GAAP net income of $76.2 million, or $2.13 per share, down from $106.7 million, or $2.94 per share, a year earlier. Excluding derivative market value adjustments, net income was $67.9 million, or $1.89 per share, compared with $2.95 per share in the prior-year quarter. The company also declared a $0.36 per share fourth-quarter dividend, payable December 15, 2026.
GAAP EPS was $2.13 for Q3 2026, versus $2.94 in Q3 2025
Excluding derivative market value adjustments, EPS was $1.89, versus $2.95 a year earlier
Loan Servicing and Systems revenue was $139.8 million, down from $151.1 million, including $32.9 million of prior-year Department of Education contract modifications
Fourth-quarter dividend of $0.36 per share is payable December 15, 2026, to holders of record on December 1, 2026
Dentsply Sirona reported third-quarter 2026 net sales of $836 million, down 7.6% from $904 million a year earlier, and adjusted EPS of $0.29, down 29.4% from $0.42. GAAP results improved from a year earlier, when large impairment charges produced a $427 million net loss attributable to the company, but the company's cash flow weakened and it updated its 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30.
Net sales were $836 million, down 7.6% as reported and down 7.0% in constant currency.
GAAP diluted loss was $0.01 per share, compared with a $2.14 loss per share a year earlier; adjusted EPS was $0.29 versus $0.42.
The 2026 outlook calls for approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding a $0.17 one-time benefit from tariff refunds.
Operating cash flow was $32 million versus $79 million, and free cash flow was $0 million versus $40 million; the company repurchased shares for approximately $13 million.
LB Pharmaceuticals reported a third-quarter 2026 net loss of $59.1 million, or $1.79 per share, compared with $3.6 million a year earlier, as research and development spending rose to $51.5 million from $2.4 million. The company reported cash, cash equivalents and short-term investments of $403.8 million and said this should fund operations beyond the second quarter of 2029, while it remains on track for topline data from the Phase 3 NOVA-2 trial in the first half of 2027.
Net loss was $59.1 million for the quarter ended September 30, 2026, versus $3.6 million a year earlier; net loss per share was $1.79 versus $0.61.
Research and development expenses were $51.5 million, versus $2.4 million, mainly for the Phase 3 trial of LB-102 in acute schizophrenia and the Phase 2 bipolar depression trial.
Cash, cash equivalents and short-term investments were $403.8 million as of September 30, 2026, up from $295.2 million at December 31, 2025.
Topline data from the Phase 3 NOVA-2 trial are expected in the first half of 2027.
Phio Pharmaceuticals reported a third-quarter 2026 net loss of $4.2 million, up from $2.4 million a year earlier, as research and development costs for its PH-762 program rose sharply. Cash and cash equivalents fell to $10.6 million at September 30, 2026, from $21.0 million at December 31, 2025, and the company's stockholders' equity declined to $8.6 million, so shareholders face a larger loss and a smaller cash balance.
Q3 2026 research and development expenses were $3.0 million, up $1.9 million or 159% from the prior-year quarter, driven mainly by nonclinical toxicology, drug substance and clinical supply costs.
Nine-month 2026 net loss was $12.3 million, compared with $6.3 million in the same period of 2025.
Cash and cash equivalents were $10.6 million at September 30, 2026, versus $21.0 million at December 31, 2025.
The company expects FDA feedback on its submission by the end of November 2026 and plans to start the Phase 2b study of PH-762 in the first quarter of 2027.
Organogenesis reported third quarter 2026 net product revenue of $45.5 million, down 70% from $150.5 million a year earlier, and a net loss of $29.6 million, compared with net income of $21.6 million in the prior-year quarter. The company also updated its full-year 2026 revenue outlook to $179.4 million to $200.0 million, a decline of 65% to 68%, which it said reflects a more measured fourth-quarter recovery than its prior guidance assumed.
Net product revenue was $45.5 million for the quarter ended September 30, 2026, versus $150.5 million a year earlier; Advanced Wound Care fell 73% to $38.2 million.
Net loss was $29.6 million, or $(0.25) per share, versus net income of $21.6 million, or $0.11 per share, in the third quarter of 2025.
As of September 30, 2026, cash, cash equivalents and restricted cash totaled $26.9 million, with no outstanding debt obligations.
Full-year 2026 net revenue guidance is $179.4 million to $200.0 million, versus $564.2 million in 2025.
Enliven Therapeutics reported a third-quarter 2026 net loss of $27.7 million, up from $20.1 million a year earlier, as research and development and general and administrative expenses rose. The company said it reached alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial and remains on track to start the trial before year-end 2026, with $884.4 million in cash, cash equivalents and marketable securities expected to fund operations into 2030.
Q3 2026 net loss was $27.7 million, or $0.36 per share, versus $20.1 million, or $0.32 per share, in Q3 2025
R&D expenses were $28.0 million in Q3 2026, compared with $18.2 million in Q3 2025
Cash, cash equivalents and marketable securities totaled $884.4 million as of September 30, 2026, with runway expected into 2030
ENABLE-2 start is targeted before year-end 2026 following FDA alignment on trial design
IN8bio reported third quarter 2026 results on November 5, 2026. The net loss widened to $4.6 million from $3.9 million a year earlier, as research and development expenses rose to $2.6 million from $2.1 million, mainly due to preclinical costs for its T cell engager platform. Cash was $14.0 million at September 30, 2026, down from $27.1 million at December 31, 2025, and the company has no revenue reported in the filing, so shareholders face a higher loss and a shrinking cash balance.
Net loss of $4.6 million, or $0.24 per share, versus $3.9 million, or $0.85 per share, a year earlier
R&D expenses of $2.6 million versus $2.1 million, driven mainly by preclinical T cell engager costs
Cash of $14.0 million at September 30, 2026, versus $10.7 million a year earlier and $27.1 million at December 31, 2025
Company remains on track to report initial in vivo preclinical data for INB-619 by year-end 2026
Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, up from a net loss of $41.4 million, or $0.19 per share, a year earlier. The company reported no collaboration revenue and said its cash, cash equivalents and investments of $388.9 million fund its operations into 2029, while its 2026 GAAP operating expense outlook is about $225 million.
Q3 2026 net loss was $50.4 million, or $0.15 per share, versus $41.4 million, or $0.19 per share, in Q3 2025
Research and development expenses were $41.9 million and general and administrative expenses were $12.9 million in Q3 2026
Cash, cash equivalents and investments were $388.9 million as of September 30, 2026; cash runway projected into 2029
2026 guidance: operating expense about $165 million; GAAP operating expenses about $225 million, including about $35 million of stock-based compensation
Inogen reported third-quarter 2026 results with revenue down 2.4% and a larger GAAP loss from continuing operations than a year earlier, including a $10.6 million impairment charge. The company also completed the sale of its U.S. oxygen rental business and named Andy Reding as President and CEO, replacing Kevin Smith.
Q3 2026 revenue was $77.2 million, down from $79.1 million; U.S. sales rose 3.8% while international sales fell 9.0%.
GAAP loss from continuing operations was $14.8 million ($0.56 per diluted share) versus $3.6 million ($0.13) a year earlier.
Fourth-quarter 2026 revenue from continuing operations is expected at $65 million to $68 million; full-year revenue at $298 million to $301 million, with an adjusted loss of $7 million to $8 million.
Andy Reding became President and CEO effective October 30, 2026; the company also plans a $20 million annualized cost reduction program starting in Q4 2026.
BRC Group reported a third-quarter 2026 net loss available to common shareholders of $243.0 million, or $(6.04) per diluted share, compared with net income of $89.1 million a year earlier. The loss mainly reflected $226.7 million of pre-tax losses on its Babcock & Wilcox investment, and nine-month total revenues fell 9% to $624.2 million. The company also completed the sale of its remaining GA Group interest on November 3, 2026, which reduced Oaktree term-loan debt.
Q3 2026 total revenues were $33.0 million: Operating Revenues of $161.3 million were offset by investment losses of $128.3 million.
Nine-month 2026 net loss available to common shareholders was $(13.2) million, or $(0.40) per diluted share, versus net income of $214.5 million in the prior-year period.
On November 3, 2026, the company sold its GA Group interest for $62.3 million in cash, reducing outstanding Oaktree term loans to $43.7 million from $65.6 million.
A definitive agreement to acquire Sangoma Technologies was signed September 28, 2026, at a total enterprise value of $203.7 million, and is expected to close no later than early 2027.
CytomX reported unaudited third-quarter 2026 results with revenue of $1.7 million, down from $6.0 million a year earlier, as the Astellas collaboration performance obligation concluded in the second quarter of 2026. The net loss widened to $20.0 million from $14.2 million, while operating expenses rose to $25.2 million, and the company ended the quarter with $348.0 million in cash, cash equivalents and investments, with cash runway expected into the second half of 2028.
Q3 2026 revenue was $1.7 million versus $6.0 million in Q3 2025; nine-month revenue was $13.4 million versus $75.5 million.
Q3 2026 net loss was $20.0 million, or $0.09 per share, versus a net loss of $14.2 million, or $0.09 per share, a year earlier.
Operating expenses rose to $25.2 million from $21.7 million, led by research and development at $16.5 million and general and administrative at $8.7 million.
Varseta-M received FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer in August 2026; a Phase 1 monotherapy data update is expected in January 2027.
GSI Technology reported second-quarter fiscal 2027 net revenue of $6.0 million, down from $6.4 million a year earlier, while its net loss widened to $7.0 million from $3.2 million. Gross margin fell below the company's own guidance, and it expects third-quarter gross margin of approximately 38% to 40%, which points to continued pressure on profitability for shareholders.
Net revenue was $6.0 million, within guidance of $5.7 million to $6.5 million, but below $6.4 million a year earlier.
Gross margin was 48.5% versus 54.8% a year earlier and below guidance of about 53% to 55%; net loss was $(0.18) per diluted share versus $(0.11).
Third-quarter fiscal 2027 outlook: net revenues of $5.0 million to $6.0 million and gross margin of about 38% to 40%, with price increases for new orders immediately and for existing backlog effective January 1, 2027.
Cash and cash equivalents were $69.2 million at September 30, 2026, versus $67.2 million at March 31, 2026.
Yelp reported third-quarter 2026 results on November 5, 2026, with net revenue of $371 million, down 1% from a year earlier, and net income of $35 million, down 12%. Diluted earnings per share rose to $0.63 from $0.61, and adjusted EBITDA fell 6% to $92 million. Yelp also updated its 2026 outlook to net revenue of $1.455 billion to $1.460 billion and adjusted EBITDA of $320 million to $325 million, but the filing does not state the prior outlook, so the direction of the change cannot be determined.
Net revenue was $371 million, down 1% from $376 million, and $1 million above the high end of the company's third-quarter outlook range.
Net income was $35 million, versus $39 million a year earlier; diluted EPS was $0.63, versus $0.61.
Adjusted EBITDA was $92 million, down 6% from $98 million, with a 25% margin.
For 2026, Yelp expects net revenue of $1.455 billion to $1.460 billion and adjusted EBITDA of $320 million to $325 million.
Celcuity reported a third-quarter 2026 net loss of $73.3 million, or $1.33 per share, up from $43.8 million, or $0.92 per share, a year earlier. The company recognized no product revenue in the quarter because REVTORPYK shipments began on September 30, 2026, and revenue is recognized only on delivery, so the larger loss reflects launch spending.
Net loss was $73.3 million, or $1.33 per share, versus $43.8 million, or $0.92 per share, in Q3 2025.
No REVTORPYK product revenue was recognized in the quarter; shipments began September 30, 2026.
SG&A expenses rose to $39.8 million from $12.4 million, with $25.3 million of the increase tied to commercialization.
Cash, cash equivalents and short-term investments were $642.7 million at September 30, 2026, which the company expects will fund operations through 2029.
Wynn Resorts reported third quarter 2026 operating revenues of $1.69 billion and net income of $17.3 million, down from $1.83 billion and $88.3 million in the prior-year period. The company also declared a cash dividend of $0.25 per share payable on November 30, 2026.
Operating revenues decreased to $1.69 billion for Q3 2026 from $1.83 billion in Q3 2025.
Net income attributable to Wynn Resorts fell to $17.3 million, or $0.17 per diluted share.
Board of directors declared a cash dividend of $0.25 per share, payable on November 30, 2026.
Life-to-date cash contributions to the Wynn Al Marjan Island development reached $1.12 billion.
Nutex Health reported third-quarter 2026 results, with total revenue down 18.7% to $217.6 million from $267.8 million a year earlier. Net income attributable to the company fell to $40.2 million, or $5.71 per diluted share, from $55.4 million, or $7.76, in the same quarter of 2025. Both headline revenue and profit declined, and the company did not provide guidance in this filing.
Q3 2026 total revenue was $217.6 million, down 18.7% from $267.8 million; same-hospital hospital division revenue fell 20.1%.
Q3 2026 net income attributable to Nutex Health was $40.2 million, or $5.71 diluted EPS, versus $55.4 million, or $7.76, a year earlier.
Nine-month net income attributable to Nutex Health rose to $152.9 million, or $21.50 diluted EPS, helped by a $52.3 million change in estimate tied to the HaloMD agreement amendment.
The company will host a conference call on Friday, November 6, 2026 at 9:30 a.m. CT.
Corvus Pharmaceuticals reported a third-quarter 2026 net loss of $20.3 million, up from $10.2 million a year earlier, as research and development expenses rose to $17.8 million from $8.5 million. The company had $202.9 million in cash, cash equivalents and marketable securities at September 30, 2026, which it says will fund operations into the second quarter of 2028.
Q3 2026 net loss was $20.3 million, or $0.22 per share, versus $10.2 million, or $0.12 per share, in Q3 2025.
Research and development expenses were $17.8 million for the quarter, up $9.3 million, mainly from higher clinical trial costs for soquelitinib.
Cash, cash equivalents and marketable securities were $202.9 million at September 30, 2026, including about $189.4 million in net proceeds from a financing completed January 23, 2026.
The company said its cash is expected to fund operations into the second quarter of 2028.
Cardlytics reported third-quarter 2026 revenue of $32.9 million, down 30% from a year earlier, and billings of $57.2 million, down 32%. CEO Amit Gupta said results came in below expectations, and the company guided fourth-quarter revenue to $35.0 million to $39.0 million, which is still a year-over-year decline, though management expects sequential growth.
Q3 2026 revenue was $32.9 million, down 30% from $47.0 million in Q3 2025; billings were $57.2 million, down 32%.
Net loss narrowed to $(8.9) million from $(72.7) million a year earlier, when results included a $58.8 million impairment of goodwill and intangible assets.
Adjusted EBITDA was $0.4 million, compared with $3.3 million in Q3 2025.
Q4 2026 guidance: revenue of $35.0 million to $39.0 million (down 31% to 23% year over year) and Adjusted EBITDA of $(1.0) million to $2.0 million.
Celldex reported third-quarter 2026 results with a net loss of $75.6 million, or $0.96 per share, up from $67.0 million, or $1.01 per share, a year earlier. The company recognized no material revenue, while research and development expenses rose to $67.4 million, and cash, cash equivalents and marketable securities declined to $650.3 million; the company says this funds planned operations through 2028.
Q3 2026 net loss was $75.6 million ($0.96 per share), compared with $67.0 million ($1.01 per share) in Q3 2025.
Q3 2026 R&D expenses were $67.4 million, up from $62.9 million, driven mainly by barzolvolimab clinical trial and contract manufacturing costs.
Cash and marketable securities were $650.3 million at September 30, 2026, down from $717.6 million at June 30, 2026.
The company expects to submit a BLA for barzolvolimab in chronic spontaneous urticaria (CSU) in 2027.
CION reported a net decrease in net assets from operations of $3.55 million, or $(0.07) per share, for the third quarter of 2026, compared with earnings of $0.62 per share in the second quarter. Net asset value per share fell to $13.20 from $13.57, and total investment income declined to $48.3 million from $49.8 million, although the company reduced total debt to $897 million from $1.17 billion. Co-chief executive officers also declared base distributions of $0.25 per share for the first quarter of 2027, below the $0.30 per share declared for the third quarter of 2026.
Q3 2026 net decrease in net assets from operations was $3.55 million, or $(0.07) per share, versus earnings of $0.62 per share in Q2 2026.
Net asset value per share was $13.20 at September 30, 2026, down from $13.57 at June 30, 2026.
Base distributions for Q1 2027 total $0.25 per share, payable in three monthly amounts from January 29 to March 26, 2027.
Total debt fell to $897 million from $1.17 billion, and the net debt-to-equity ratio was 1.30x versus 1.52x.
Intellia Therapeutics reported third-quarter 2026 results, with collaboration revenue of $7.2 million, down from $13.8 million a year earlier, and a net loss of $127.5 million, up from $101.3 million. The company said cash, cash equivalents and marketable securities were $614.8 million at September 30, 2026, and that existing resources should fund operations at least into 2028.
Collaboration revenue fell to $7.2 million from $13.8 million, mainly due to lower Regeneron revenue.
Net loss was $127.5 million, including a $10.4 million unrealized loss from changes in investment fair value.
Cash and marketable securities were $614.8 million at September 30, 2026, which the company expects to fund operations at least into 2028.
FDA set a PDUFA target action date of March 10, 2027 for lonvo-z in HAE.
White Mountains Insurance Group reported a net loss attributable to common shareholders of $39 million for the third quarter of 2026, compared with income of $114 million a year earlier, and book value per share fell 1% to $2,243 as of September 30, 2026. Unrealized investment losses, including a $54 million mark-to-market loss on its MediaAlpha stake after a 24% share price decline, drove the result, which matters to shareholders because the book value per share is the company's main measure of value.
Third-quarter 2026 net income (loss) attributable to common shareholders was $(39) million, versus $114 million in Q3 2025; first nine months were $133 million, versus $271 million.
Third-quarter total revenues were $641 million, down from $864 million in Q3 2025.
Book value per share was $2,243 at September 30, 2026, down 1% for the quarter and up 3% for the first nine months, including dividends.
On November 4, 2026, the company agreed to sell 5.5 million MediaAlpha shares at $13.90 per share, leaving it with 12.4 million shares.
BlackRock TCP Capital Corp. reported a third quarter 2026 net decrease in net assets from operations of $66.8 million, or $0.80 per share, compared with a $1.7 million net increase in the prior quarter. Net asset value per share fell to $5.61 from $6.58 at June 30, 2026, and the company's board declared a fourth quarter dividend of $0.17 per share while the board conducts an ongoing strategic review.
Net decrease in net assets from operations of $66.8 million, or $0.80 per share, for the quarter ended September 30, 2026, versus a $1.7 million net increase for the quarter ended June 30, 2026.
Net investment income of $13.4 million, or $0.16 per share, which did not exceed the regular dividend of $0.17 per share.
Net asset value per share of $5.61 as of September 30, 2026, compared with $6.58 as of June 30, 2026.
Investments on non-accrual status were 3.4% of the portfolio at fair value, up from 1.6%; the quarter included a $63.7 million realized loss from the Continuation Vehicle transaction.
Shattuck Labs reported a third-quarter 2026 net loss of $25.2 million, or $0.14 per share, up from $10.1 million a year earlier, as research and development spending rose to $21.6 million from $7.6 million. The company had no revenue in the quarter, compared with $1.0 million of related party license revenue a year earlier, and said its $196.3 million in cash, cash equivalents and short-term investments should fund operations into 2029.
Net loss of $25.2 million, or $0.14 per share, for the quarter ended September 30, 2026, versus a net loss of $10.1 million, or $0.14 per share, a year earlier.
R&D expenses were $21.6 million versus $7.6 million; there was no license revenue in Q3 2026 compared with $1.0 million in Q3 2025.
Cash, cash equivalents and short-term investments were $196.3 million at September 30, 2026, versus $86.1 million a year earlier.
RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease was initiated; RECEPTIVE-HS1 Phase 2 trial start is expected in Q4 2026.
Globalstar reported third-quarter 2026 results that were weaker than a year earlier, with revenue, operating income, adjusted EBITDA and net income all declining from the prior-year quarter. The company also said it will no longer hold earnings calls or update forward-looking guidance while its pending transaction with Amazon is outstanding, which limits the information shareholders will receive before the expected 2027 closing.
Q3 2026 total revenue was $70.9 million, down from $73.8 million in Q3 2025; service revenue fell $4.2 million.
Q3 2026 net loss was $15.7 million, or $0.14 per share, versus net income of $1.1 million a year earlier.
Q3 2026 adjusted EBITDA was $30.3 million, down from $37.6 million; nine-month revenue rose to $205.7 million from $201.0 million.
Globalstar will not hold future earnings conference calls or update guidance, given the pending Amazon transaction expected to close in 2027.
Intensity Therapeutics reported a third quarter 2026 net loss of $3.5 million, up from $2.7 million a year earlier, as research and development spending rose to $2.4 million. The company ended the quarter with $8.5 million in cash and cash equivalents and said it raised $1.5 million in net proceeds through its at-the-market facility during the quarter, while it resumed patient enrollment in two clinical trials.
Net loss was $3.5 million for Q3 2026, compared with $2.7 million for Q3 2025.
Research and development expenses were $2.4 million, compared with $1.6 million a year earlier, mainly due to higher INVINCIBLE-3 Study costs.
Cash and cash equivalents were $8.5 million as of September 30, 2026, down from $11.9 million at December 31, 2025.
The company raised $1.5 million in net proceeds under its $60 million at-the-market facility in Q3 2026.
Teads Holding Co. reported third-quarter 2026 revenue of $235.1 million, down 26% from a year earlier, and a net loss of $325.5 million, which included a $272.4 million non-cash goodwill impairment charge. The company has suspended guidance, including its full-year 2026 Adjusted EBITDA guidance, and is not providing an outlook. It also named Michael Coyle as chief financial officer, effective November 11, 2026, succeeding Jason B. Kiviat.
Revenue $235.1 million vs. $318.8 million a year earlier; gross profit $60.9 million vs. $105.7 million.
Net loss $325.5 million vs. $19.7 million, including a $272.4 million goodwill impairment; Adjusted EBITDA was $(8.1) million vs. $19.2 million.
Full-year 2026 guidance, including Adjusted EBITDA guidance, has been suspended and is not being provided.
Michael Coyle becomes CFO effective November 11, 2026; Jason B. Kiviat ceases as CFO on November 10, 2026 and moves to an advisory role.
Dyne Therapeutics reported a third-quarter 2026 net loss of $193.6 million, or $1.06 per share, up from $108.0 million, or $0.76 per share, a year earlier. The increase reflects higher research and development and general and administrative costs as the company prepares for a possible U.S. launch of z-rostudirsen, and the filing reports $1.134 billion in cash and marketable securities.
Q3 2026 net loss was $193.6 million, or $1.06 per share, compared with $108.0 million, or $0.76 per share, in Q3 2025.
R&D expenses rose to $161.7 million from $97.2 million, driven by manufacturing for z-rostudirsen and Phase 3 trial costs.
G&A expenses rose to $35.3 million from $16.7 million, mainly for launch preparation and higher headcount.
Cash, cash equivalents and marketable securities were $1.134 billion at September 30, 2026, which the company says will fund operations into Q2 2028.
Cogent Communications reported third-quarter 2026 service revenue of $231.2 million, down 1.8% from the second quarter and down 4.4% from a year earlier, and a net loss of $(0.62) per share. The company's board suspended its quarterly dividend on November 4, 2026, which removes a cash return for shareholders. Adjusted EBITDA rose 3.9% sequentially to $73.9 million, but the second quarter included a $130.7 million gain on a sale of data centers, so the sequential EPS comparison is distorted.
Service revenue was $231.2 million for Q3 2026, versus $235.6 million for Q2 2026 and $241.9 million... see note: Q3 2025 service revenue was not stated as a figure in the release text, so use only the reported percentage decline of 4.4% ye
Basic net loss per share was $(0.62) for Q3 2026, compared with basic net earnings of $1.39 in Q2 2026 and a basic net loss of $(0.87) in Q3 2025.
EBITDA, as adjusted, was $73.9 million, up 3.9% from Q2 2026, with a margin of 32.0%.
The Board voted on November 4, 2026 to suspend the dividend program.
Shutterstock reported third-quarter 2026 revenue of $173.9 million, down 33% from $260.1 million a year earlier, and a net loss of $197.8 million, including a $195.6 million after-tax goodwill impairment charge. Chief Financial Officer Rik Powell is leaving, with Scott Grossman named Interim Chief Financial Officer, which adds leadership change to a quarter of sharp declines in revenue and earnings.
Revenue was $173.9 million versus $260.1 million; Content revenue fell 19% to $158.1 million and Data, Distribution, and Services fell 76% to $15.8 million.
Net loss per diluted share was $5.35 versus net income of $0.37; adjusted net income per diluted share was $0.45 versus $0.99.
Adjusted EBITDA was $41.8 million versus $79.4 million; cash and cash equivalents were $110.5 million at September 30, 2026.
Rik Powell ceased to serve as CFO effective November 2, 2026 and departs November 13, 2026; Scott Grossman is interim CFO with a base salary of $450,000.
Aclaris Therapeutics reported third-quarter 2026 results on November 5, 2026, with a net loss of $18.5 million, up from $14.6 million a year earlier, and total revenue of $1.5 million, down from $3.3 million. The company said the revenue decline was mainly due to a sales milestone under the Sun Pharma license agreement recorded in the 2025 periods, while research and development spending rose on the ATI-052 program. Cash, cash equivalents and marketable securities were $204.6 million at September 30, 2026, and the company said this, plus an October 2026 offering, should fund operations through the first half of 2029.
Q3 2026 net loss was $18.5 million versus $14.6 million in Q3 2025; nine-month net loss was $59.8 million versus $45.1 million.
Q3 2026 total revenue was $1.5 million versus $3.3 million; nine-month revenue was $5.1 million versus $6.5 million.
Q3 2026 R&D expenses were $16.1 million versus $13.0 million, driven mainly by ATI-052 costs.
October 2026 offering raised $50.0 million in aggregate gross proceeds; company expects cash to last through the first half of 2029.
McGraw Hill reported fiscal second quarter 2027 results for the period ended September 30, 2026. Revenue fell 5.5% year over year to $632.2 million, net income declined to $86.4 million from $105.3 million, and adjusted EBITDA dropped to $250.6 million from $286.4 million. The company reaffirmed its fiscal 2027 guidance, which shareholders will watch for signs of the expected revenue recovery.
Q2 revenue of $632.2 million, down 5.5% from $669.2 million a year earlier; year-to-date revenue down 1.9%
GAAP net income of $86.4 million, versus $105.3 million in the prior-year quarter; diluted EPS $0.45 versus $0.57
Adjusted EBITDA of $250.6 million (39.6% margin), versus $286.4 million (42.8% margin) a year earlier
Fiscal 2027 guidance reaffirmed: revenue $2.115 billion to $2.175 billion; adjusted EBITDA $750 million to $790 million
Akebia Therapeutics reported third-quarter 2026 results on November 5, 2026. Total revenues fell to $36.9 million from $58.8 million a year earlier, and the company posted a net loss of $14.4 million compared with net income of $0.5 million, mainly due to lower Auryxia sales. Vafseo patient count rose to about 11,500, but Vafseo revenue was pressured by a customer inventory reduction.
Auryxia net product revenues were $20.0 million, down from $42.5 million in Q3 2025; the company expects Auryxia revenues to decline in 2026.
Vafseo net product revenues were $14.8 million, compared with $14.3 million in Q3 2025.
Net loss per share was $0.05, compared with $0.00 per share in net income a year earlier; results include a $1.3 million restructuring charge.
Cash and cash equivalents were $159.3 million at September 30, 2026, and the company plans to refinance its senior secured term loan facility.
Wendy's reported third-quarter 2026 results for the quarter ended September 27, 2026, with total revenues of $547.0 million, down 0.5%, and net income of $15.1 million, down 65.9% from a year earlier. The company also launched its multi-year Dave's Way strategy and signed a letter of intent to acquire up to 163 restaurants from Meritage Hospitality Group, subject to a definitive agreement and court approval. The profit decline matters to shareholders because diluted earnings per share fell to $0.08 from $0.23, and the company did not repurchase shares in the quarter.
Diluted EPS was $0.08 versus $0.23 a year earlier; adjusted EPS was $0.13 versus $0.24.
Global systemwide sales fell 5.9%, and U.S. same-restaurant sales fell 5.7%.
Adjusted EBITDA was $113.4 million, down 17.8%; year-to-date free cash flow was $174.2 million.
No shares were repurchased in the third quarter; about $35.0 million remains under an authorization expiring in February 2027. A quarterly dividend of $0.07 per share is payable December 15, 2026.
Tripadvisor reported third-quarter 2026 revenue of $436.4 million, down 11% year-over-year, and a GAAP net loss of $316.9 million, driven mainly by a $369.5 million non-cash goodwill impairment in its Hotels and Other segment. The company also closed the sale of TheFork on November 1, 2026 for approximately $741.0 million in net cash, and management expects to prioritize reducing long-term debt; a restructuring plan is expected to yield about $40 million in annualized gross savings.
Revenue was $436.4 million, down 11% from $490.8 million; Experiences fell 3% and Hotels and Other fell 23%.
GAAP net loss was $316.9 million, or $(2.70) per diluted share, including the $369.5 million goodwill impairment.
Non-GAAP net income was $43.4 million, or $0.37 per diluted share, down 36% from $0.58 a year earlier.
TheFork sale closed November 1, 2026 for approximately $741.0 million net cash; restructuring costs are estimated at $15 million to $20 million, mainly in Q4 2026.
1-800-FLOWERS.COM reported fiscal 2027 first-quarter revenue of $171.4 million, down 11.1% from the prior year, and a net loss from continuing operations of $50.6 million, or $0.79 per diluted share, versus $49.0 million, or $0.77 per share, a year earlier. The company also cut its fiscal 2027 outlook to a revenue decline of 2% to 5% and Adjusted EBITDA of $10 million to $15 million, reflecting the divestiture of PersonalizationMall.com and Things Remembered.
Revenue fell 11.1% to $171.4 million; gross profit margin declined 120 basis points to 34.1%
Net loss from continuing operations was $50.6 million ($0.79 per share) vs. $49.0 million ($0.77 per share) a year earlier; Adjusted EBITDA loss was $31.9 million vs. $31.7 million
Fiscal 2027 outlook: total revenues expected to decline 2% to 5% and Adjusted EBITDA of approximately $10 million to $15 million
Agreement to sell the Jacksonville, FL facility for approximately $10 million, subject to due diligence and closing conditions
Lexicon Pharmaceuticals reported third-quarter 2026 revenue of $11.3 million, down from $14.2 million a year earlier, and a net loss of $14.0 million, up from $12.8 million. The company completed enrollment in its Phase 3 SONATA-HCM study and expects topline results in the first quarter of 2027.
Total revenues were $11.3 million, including $10.0 million of development milestone revenue from Novo, versus $14.2 million in the third quarter of 2025.
Net loss was $14.0 million, or $0.03 per share, compared with $12.8 million, or $0.04 per share, a year earlier.
Cash and investments were $183.2 million at September 30, 2026, and SONATA-HCM enrolled 542 patients.
Keel Infrastructure reported third-quarter 2026 results with revenue of $28 million, down from $68 million a year earlier, as it stopped U.S. Bitcoin mining to focus on HPC/AI data centers. Loss from continuing operations widened to $62 million, or $0.10 per share, from $11 million, or $0.02 per share, mainly due to a $55 million non-cash unrealized loss on capped calls, and Adjusted EBITDA was negative $27 million versus $19 million a year earlier.
Q3 2026 revenue was $28 million, down from $68 million in Q3 2025; the company cited the cessation of U.S. Bitcoin mining in Q2 2026 and lower average Bitcoin prices.
Loss from continuing operations was $62 million, or $0.10 per share, compared with $11 million, or $0.02 per share, in Q3 2025.
Operating loss narrowed to $8 million from $18 million, while general and administrative expenses rose to $34 million from $17 million.
As of November 4, 2026, unrestricted cash liquidity was approximately $780 million; the company sold 2,520 Bitcoin for $192 million during the quarter.
Tenax Therapeutics reported a third-quarter 2026 net loss of $16.7 million, up from $15.8 million a year earlier, and no revenue was reported. The company paused enrollment in its ongoing LEVEL-2 Phase 3 trial while it amends the protocol to target a narrower patient group, and it has a Type C meeting with the FDA pending. Shareholders face a larger loss and a trial whose future plan depends on that FDA meeting.
Net loss for the quarter ended September 30, 2026 was $16.7 million, compared with $15.8 million for the same quarter of 2025.
Research and development expenses rose to $12.1 million from $10.3 million; SG&A fell to $5.7 million from $6.5 million.
Cash and cash equivalents were $113.7 million at September 30, 2026; the company expects cash to fund operations through fiscal 2028, subject to the FDA Type C meeting outcome.
LEVEL-2 enrollment is temporarily paused after the LEVEL trial did not meet its primary endpoint, announced August 10, 2026.
Wheels Up reported third-quarter 2026 revenue of $164.8 million, down 11% from a year earlier, and a net loss of $89.4 million, wider than the $83.7 million loss in the prior-year period. The company also disclosed a new $100 million revolving credit facility from Delta Air Lines that accrues 10% interest payable in kind and matures December 1, 2027, along with an order for six Embraer jets with an aggregate price of approximately $90.0 million. For shareholders, headline losses grew and the company is adding debt, though its Adjusted EBITDAR loss narrowed.
Q3 2026 revenue was $164.8 million, down 11% year over year; net loss was $89.4 million, or $(2.48) per share, versus $83.7 million a year earlier.
Adjusted EBITDAR loss narrowed to $13.2 million from $23.4 million; Adjusted Contribution Margin rose to 16.4% from 12.7%.
Delta committed an additional $100 million revolving credit facility under Amendment No. 6, dated November 4, 2026, with 10% per annum interest payable in kind and a scheduled maturity of December 1, 2027.
Six Phenom 300E jets were ordered from Embraer for approximately $90.0 million, with deliveries expected in the third and fourth quarters of 2027; a $17.4 million PDP Equipment Notes issuance funded the deposit.
Chimera Investment Corporation (NYSE: CIM) reported a GAAP net loss available to common shareholders of $194 million, or $2.31 per diluted share, for the quarter ended September 30, 2026, compared with a loss of $22 million, or $0.27 per share, a year earlier. The company said significant movements in interest rates and mortgage spreads affected its book value, which was $14.82 per common share, and its economic return for the quarter was (13.98)%. Its non-GAAP earnings available for distribution were $32 million, or $0.38 per adjusted diluted share, compared with $0.37 a year earlier.
GAAP net loss available to common shareholders of $194 million, or $2.31 per diluted share, versus a $22 million loss, or $0.27 per share, in Q3 2025
Earnings available for distribution of $32 million, or $0.38 per adjusted diluted share (non-GAAP), versus $0.37 in Q3 2025
Net unrealized losses on financial instruments at fair value of $391 million in the quarter
Subsequent to quarter end, completed the inaugural $291 million Prism securitization backed by loans originated by HomeXpress
Zai Lab reported third-quarter 2026 total revenue of $108.2 million, down from $116.1 million a year earlier, and a net loss of $46.1 million, or $0.04 per ordinary share, compared with $36.0 million, or $0.03, in the prior-year quarter. The company attributed the larger loss mainly to $13.6 million in inventory write-downs and said it completed a private placement with gross proceeds of about $250.0 million in October 2026.
Total revenue was $108.2 million, versus $116.1 million in Q3 2025; net product revenue rose 2% from Q2 2026.
Net loss was $46.1 million ($0.04 per share), versus $36.0 million ($0.03 per share) a year earlier, mainly due to $13.6 million in inventory write-downs.
Private placement of 11,340,000 ADSs at $22.04 each closed October 27, 2026, with net proceeds of about $241.2 million.
Cash, restricted cash and short-term investments totaled $659.7 million at September 30, 2026, down from $717.5 million at June 30, 2026.
United Parks & Resorts reported third-quarter 2026 results, with total revenue of $506.5 million, down 1.1%, and net income of $80.0 million, down 10.5% from the third quarter of 2025. Attendance fell 4.7% to 6.5 million guests, which the company attributed to weather, calendar effects, lower international visitation and a planned reduction in promotional admissions. Diluted earnings per share rose to $1.74 from $1.61, and the filing contains no updated financial guidance.
Q3 2026 total revenue was $506.5 million, down $5.4 million or 1.1% from Q3 2025.
Q3 2026 net income was $80.0 million, down 10.5%, while diluted EPS rose to $1.74 from $1.61.
Q3 2026 attendance was 6.5 million guests, down 4.7%, while total revenue per capita rose 3.8% to $78.29.
First nine months 2026 net income was $109.2 million, down 28.8%, and Adjusted EBITDA was $458.6 million, down 6.4%.
Regis Corporation reported fiscal first-quarter 2027 results for the quarter ended September 30, 2026, with consolidated revenue of $54.3 million, down from $59.0 million a year earlier, and diluted EPS of $0.18 versus $0.49. Operating income fell to $5.3 million, including a $2.5 million accrual tied to a Department of Justice inquiry about a PPP loan obtained by Alline before Regis acquired it. The company said it decided not to refinance now and expects to return to the debt markets in early calendar 2027.
Consolidated revenue $54.3 million vs. $59.0 million; franchise rental income and company-owned salon revenue were the main drivers
Diluted EPS $0.18 vs. $0.49; adjusted diluted EPS $0.48 vs. $0.50
$2.5 million accrual related to a DOJ inquiry on an Alline PPP loan, which the company excludes from adjusted results
Company-owned same-store sales (1.1)%; cash at quarter end $20.8 million; $7.9 million of debt repaid in the quarter
Ingredion reported third quarter 2026 diluted EPS of $2.23, down from $2.61 a year earlier, and net sales of $1.79 billion, down 1%. Reported operating income fell 19% to $201 million. The company lowered its full-year 2026 outlook, citing a slower recovery at its Argo facility, higher input costs and softer demand, which points to lower earnings for shareholders.
Q3 2026 reported diluted EPS was $2.23 versus $2.61 in Q3 2025; adjusted diluted EPS was $2.28 versus $2.75.
Full-year 2026 reported diluted EPS guidance is now $8.04 to $8.49; adjusted diluted EPS guidance is now $9.25 to $9.70.
Food & Industrial Ingredients – U.S./CAN operating income is now expected to be down 35% to 40% for 2026, driven by operating costs at Argo.
Full-year 2026 cash from operations is now expected to be $650 million to $750 million.
Eve Holding, a pre-operational eVTOL aircraft developer, reported a third-quarter 2026 net loss of $58.1 million, up from $46.9 million a year earlier, mainly due to higher research and development costs and lower net financial results. The company said it expects full-year 2026 cash consumption to reach the low end of its $225 million to $275 million guidance range, and that its liquidity can fund operations through 2028.
Q3 2026 net loss was $58.1 million versus $46.9 million in Q3 2025, mainly due to higher R&D expenses and lower net financial results.
R&D expenses rose to $48.3 million from $44.9 million, while SG&A fell to $6.0 million from $7.0 million.
Q3 cash consumption was $55.1 million versus $60.7 million; full-year 2026 cash consumption is now expected at the low end of the $225 million to $275 million range.
Cash, cash equivalents and financial investments were $356.0 million at September 30, 2026; total liquidity was $470.4 million.
Walker & Dunlop reported a third-quarter 2026 net loss of $37.3 million, or $1.15 per diluted share, driven mainly by charges tied to the accelerated resolution of legacy loan repurchases and indemnifications. Total revenues fell 12% from the prior-year quarter to $298.4 million, and adjusted core EPS declined 25% to $0.92, a non-GAAP measure. The company says the GSE investigations are now complete and it plans to exit the remaining repurchased assets by early 2027.
Net loss of $37.3 million and diluted loss per share of $1.15 for Q3 2026, reflecting repurchase-related charges
Total revenues of $298.4 million, down 12% from Q3 2025; adjusted core EPS of $0.92, down 25%
Segment results include $63 million of repurchase-related charges, including $56 million of non-cash valuation adjustments
Board declared a $0.68 per share dividend for Q4 2026, payable December 4, 2026, to holders of record as of November 20, 2026
BuzzFeed reported third-quarter 2026 revenue of $26.0 million, down 44% from $46.3 million a year earlier, and a net loss of $18.7 million, compared with $7.4 million a year earlier. The company deferred its full-year 2026 financial outlook while it integrates the Allen Family Digital transaction and its July restructuring, which it expects to yield about $30 million in annualized savings.
Q3 2026 revenue was $26.0 million versus $46.3 million in Q3 2025, a 44% decline
Q3 2026 net loss was $18.7 million versus $7.4 million; Adjusted EBITDA was negative $4.8 million versus $0.8 million
Full-year 2026 financial outlook was deferred, with no new guidance provided
Restructuring is expected to yield about $30 million in annualized savings after cutting workforce and contractors by about 35%
Prospect Capital reported a net loss applicable to common shareholders of $53.4 million, or $0.10 per share, for the quarter ended September 30, 2026, compared with net income of $48.1 million, or $0.10 per share, a year earlier. Net investment income was $76.4 million, or $0.15 per common share, down from $79.4 million, or $0.17 per share, a year earlier, and net asset value per common share fell to $5.36 from $5.71 in the prior quarter and $6.45 a year earlier.
Net loss applicable to common shareholders: $(53.4) million, or $(0.10) per share, for the quarter ended September 30, 2026
Net investment income: $76.4 million, or $0.15 per share, versus $79.4 million, or $0.17 per share, a year earlier
Net asset value per common share: $5.36 at September 30, 2026, versus $5.71 at June 30, 2026 and $6.45 at September 30, 2025
Board increased the share repurchase program to up to $200.0 million on November 3, 2026; monthly common distribution declared at $0.0350 per share
Ellington Financial reported net income attributable to common stockholders of $40.4 million, or $0.31 per share, for the quarter ended September 30, 2026, down from $54.4 million, or $0.43 per share, in the second quarter. Adjusted Distributable Earnings were $58.0 million, or $0.45 per share, and book value per common share was $13.53, which the company said exceeded its $0.39 quarterly dividend in adjusted earnings. For shareholders, the lower GAAP profit reflected a sharp drop in Longbridge segment earnings and losses in Corporate/Other.
Net income attributable to common stockholders was $40.4 million, or $0.31 per share, versus $54.4 million, or $0.43 per share, in Q2 2026.
Adjusted Distributable Earnings were $58.0 million, or $0.45 per share; the investment portfolio segment contributed $77.6 million.
Longbridge segment net income fell to $12.5 million from $30.2 million in the second quarter.
Issued $150 million of 7.375% senior unsecured notes due 2030 in September, bringing the series to $550 million outstanding.
FRP Holdings reported a net loss attributable to the company of $165,000, or $(0.01) per share, for the quarter ended September 30, 2026, compared with net income of $662,000, or $0.03 per share, a year earlier. Total revenues rose 1.7% to $11.0 million, helped by a 10% increase in mining royalty revenue, but pro rata net operating income fell 5% to $9.0 million as multifamily and industrial results declined.
Q3 2026 net loss attributable to the company of $165,000, or $(0.01) per share, versus net income of $662,000, or $0.03 per share, in Q3 2025
Total revenues of $11.0 million, up 1.7%; mining royalty revenue rose 10%
Pro rata NOI fell 5% to $9.0 million; multifamily pro rata NOI fell 12% to $4.0 million
Nine-month net loss of $1,111,000, or $(0.06) per share, versus net income of $2,950,000 in the first nine months of 2025
Service Properties Trust reported a third-quarter 2026 net loss of $87.9 million, or $0.68 per share, compared with a $46.9 million loss a year earlier, and total revenues fell to $399.5 million from $478.8 million. The company also cut its midpoint full-year 2026 Normalized FFO guidance by $0.13 per share and said its board unanimously rejected an unsolicited, non-binding $2.0 billion proposal from TKO to buy its hotel portfolio, which the board believes undervalues the portfolio.
Q3 2026 net loss of $87.9 million, or $0.68 per share, versus a $46.9 million loss in Q3 2025
Q3 2026 Normalized FFO of $0.34 per share, versus $1.02 in Q3 2025; the company said this exceeded consensus estimates
Full-year 2026 Normalized FFO guidance lowered to $1.07 to $1.22 per share from $1.20 to $1.35
In October 2026 the board rejected TKO's unsolicited $2.0 billion proposal for the hotel portfolio
TriplePoint Venture Growth BDC Corp. (TPVG) reported third quarter 2026 results showing net investment income of $6.6 million, or $0.16 per share, down from $10.3 million, or $0.26 per share, a year earlier. The company posted a net decrease in net assets from operations of $1.7 million, or $0.04 per share, compared with a net increase of $15.2 million a year earlier, and net asset value fell to $8.32 per share as of September 30, 2026. For shareholders, lower investment income and a quarterly net loss weigh on earnings, though the adviser has waived its income incentive fee through fiscal 2027.
Net investment income was $6.6 million ($0.16 per share) for Q3 2026, versus $10.3 million ($0.26 per share) for Q3 2025.
Net decrease in net assets from operations was $1.7 million ($0.04 per share), compared with a $15.2 million increase in Q3 2025.
Net asset value was $8.32 per share at September 30, 2026, down from $8.73 at December 31, 2025.
The board declared a fourth quarter 2026 regular distribution of $0.23 per share, payable December 30, 2026.
Magnachip reported third-quarter 2026 revenue of $44.0 million, within its guidance range but down 4.3% from a year earlier, and a gross margin of 14.0%, below its 17% to 19% guidance range, mainly due to unfavorable foreign exchange movements. The loss from continuing operations widened to $13.3 million, or $0.36 per share, from $7.6 million in the second quarter. For shareholders, the company guided fourth-quarter gross margin to 10% to 12%, with revenue of $41.0 million to $45.0 million.
Q3 2026 net sales were $44.0 million, down 1.6% from Q2 2026 and down 4.3% from Q3 2025.
Q3 gross profit margin was 14.0%, versus guidance of 17.0% to 19.0%, and 19.3% in Q2 2026.
Q3 loss from continuing operations was $13.3 million, or $0.36 per share, compared with $7.6 million in Q2 2026.
Q4 2026 guidance: revenue of $41.0 million to $45.0 million and gross margin of 10% to 12%; the company cited a fab power shutdown tied to a substation upgrade and Korean Won appreciation.
Biote reported third-quarter 2026 revenue of $43.3 million, down 9.6% from $48.0 million a year earlier, and net income of $0.6 million, or $0.01 per diluted share, versus $9.2 million, or $0.22, in the prior-year quarter. The company kept its full-year 2026 guidance of revenue above $175 million and adjusted EBITDA above $25 million, and its interim CEO said a recent rise in procedure volume suggests demand is stabilizing, though the return to growth is progressing more slowly than anticipated.
Revenue was $43.3 million, down 9.6% from $48.0 million; procedure revenue fell 15.1% to $28.9 million while dietary supplements revenue grew 7.3% to $12.0 million.
Gross profit margin was 67.7% versus 71.8%, primarily due to residual impacts of the voluntary recall in January 2026.
Adjusted EBITDA was $5.1 million versus $12.9 million; net income was $0.6 million, or $0.01 per diluted share, versus $0.22 a year earlier.
Full-year 2026 revenue (above $175 million) and adjusted EBITDA (above $25 million) outlook remains unchanged from the second-quarter earnings release.
eHealth reported third-quarter 2026 results with total revenue of $21.3 million, down 60% from $53.9 million a year earlier, and a GAAP net loss of $35.9 million, compared with a net loss of $31.7 million in the prior-year quarter. The company reiterated its full-year 2026 guidance, which calls for total revenue of $405.0 million to $445.0 million and GAAP net income of $8.0 million to $25.0 million, and it said operating cash flow improved year over year.
Q3 2026 total revenue was $21.3 million versus $53.9 million; adjusted EBITDA was a loss of $39.9 million versus a loss of $34.0 million.
Q3 2026 operating cash flow was a use of $11.2 million, compared with a use of $25.3 million in Q3 2025; year-to-date operating cash flow was $19.6 million.
Full-year 2026 guidance was reiterated: total revenue $405.0 million to $445.0 million, GAAP net income $8.0 million to $25.0 million, adjusted EBITDA $55.0 million to $75.0 million, and operating cash flow $(10.0) million to $12.0 million.
Management said total operating costs and expenses fell 29% to $67.6 million, and it expects more than $60.0 million in annual variable spend reductions.
Universal Corporation reported results for the quarter ended September 30, 2026. Sales fell 18% to $621.8 million, and diluted earnings per share were $0.50 versus $1.36 a year earlier, as tobacco shipments were delayed by the market cycle. Management said shipments are forecast to be heavily weighted to the second half of fiscal 2027.
Quarterly sales of $621.8 million, down 18% from $754.2 million; operating income of $42.6 million, down 37%
Diluted EPS of $0.50 versus $1.36; adjusted diluted EPS (non-GAAP) of $0.39 versus $1.36
Uncommitted tobacco inventory was 19% at September 30, 2026, within the company's target range
Total debt rose to $1.20 billion and net debt (non-GAAP) to $1.15 billion, up $82.3 million from a year earlier
Genworth reported a third-quarter 2026 net loss of $41 million, or $0.11 per diluted share, compared with net income of $116 million a year earlier. Adjusted operating income excluding the Closed Block was $102 million, or $0.27 per diluted share, down from $113 million a year earlier, and the company authorized a new $500 million share repurchase program.
GAAP net loss of $41 million ($0.11 per diluted share) versus net income of $116 million ($0.28) in Q3 2025 and $47 million in Q2 2026
Adjusted operating income excluding Closed Block was $102 million ($0.27 per share), versus $113 million ($0.28) a year earlier
Closed Block adjusted operating loss of $146 million, driven by a $111 million pre-tax A/E loss from lower terminations and higher benefit utilization
Enact adjusted operating income of $132 million; Genworth repurchased $80 million of shares in the quarter and announced a new $500 million authorization
Granite Point Mortgage Trust reported a third-quarter 2026 GAAP net loss attributable to common stockholders of $60.3 million, or $12.50 per share, compared with a loss of $565 thousand, or $0.12 per share, a year earlier. The loss was driven mainly by a $45.4 million provision for credit losses, and the common dividend was declared at $0.10 per share versus $0.50 in the prior-year quarter. The company said its Board continues a previously announced review of alternatives to enhance stockholder value.
GAAP net loss attributable to common stockholders of $60.3 million, or $12.50 per basic share, for the quarter ended September 30, 2026, versus $565 thousand, or $0.12 per share, in Q3 2025
Provision for credit losses of $45.4 million; total CECL reserve of $185.9 million, or 13.7% of total loan portfolio commitments
Distributable Earnings (Loss) of $(33.7) million, or $(6.99) per share; common dividend declared at $0.10 per share versus $0.50 a year earlier
One-for-ten reverse stock split effected October 5, 2026; book value per common share was $44.54 at quarter-end
Mativ Holdings reported third-quarter 2026 sales of $499.5 million, down 2.8% from a year earlier, which the company primarily attributed to the July tornado in Wisconsin. Adjusted EBITDA fell 7% to $62.3 million and adjusted EPS was $0.31 versus $0.39, while the GAAP net loss narrowed to $1.2 million from $3.2 million, so shareholders see weaker adjusted results despite a smaller GAAP loss.
Net sales $499.5 million, down 2.8% year over year; organic sales down 2.3%
Adjusted EBITDA $62.3 million, down 7% versus $66.8 million a year earlier
GAAP net loss $1.2 million ($0.03 per share) versus $3.2 million prior year
Next quarterly dividend $0.10 per share, payable December 18, 2026, to holders of record as of November 27, 2026
Lyell Immunopharma reported a third-quarter 2026 net loss of $45.5 million, up from $38.8 million a year earlier, as research and development expenses rose to $40.9 million. Cash, cash equivalents and marketable securities fell to $194.0 million from $247.2 million at December 31, 2025, and the company announced an $80.0 million private placement that it says will fund operations into 2028.
Q3 2026 net loss was $45.5 million versus $38.8 million in Q3 2025; the company attributed the increase mainly to higher R&D spending on clinical trial activity.
R&D expenses were $40.9 million versus $28.2 million, while G&A expenses fell to $9.3 million from $10.7 million.
Cash and marketable securities were $194.0 million at September 30, 2026, down from $247.2 million at December 31, 2025.
An $80.0 million private placement was announced in November 2026, with the company expecting cash to last into 2028.
Relay Therapeutics reported a third-quarter 2026 net loss of $81.7 million, or $0.37 per share, up from a net loss of $74.1 million, or $0.43 per share, a year earlier. The company had no revenue in the quarter and ended September 30, 2026 with $848.6 million in cash, cash equivalents and investments, which it says will fund operations into 2029.
Q3 2026 net loss was $81.7 million ($0.37 per share), versus $74.1 million ($0.43 per share) in Q3 2025
R&D expenses were $77.1 million, up from $68.3 million, partly due to non-recurring costs from terminating the One Kendall Square lease
Cash, cash equivalents and investments were $848.6 million at September 30, 2026, down from $910.9 million at June 30, 2026
Phase 3 ReDiscover-2 trial in second-line breast cancer is estimated to complete enrollment in mid-2027; ASH presentation scheduled for December 14, 2026
Vaxcyte reported a third-quarter 2026 net loss of $297.1 million, or $1.99 per share, up from $212.8 million, or $1.56 per share, a year earlier, as research and development expenses rose to $270.3 million. Cash, cash equivalents and investments were $2,264.4 million at September 30, 2026, and the company says about $1.1 billion in net proceeds from October 2026 offerings is not included in that figure, bringing pro forma cash to about $3.4 billion. The release also reports positive topline data from the OPUS-1 Phase 3 trial of VAX-31 in adults, which shareholders will weigh against the higher spending.
Net loss was $297.1 million ($1.99 per share) for the quarter ended September 30, 2026, versus $212.8 million ($1.56 per share) a year earlier.
R&D expenses were $270.3 million versus $209.9 million, driven mainly by VAX-31 OPUS Phase 3 trials and manufacturing costs.
October 2026 offerings generated $1.15 billion in gross proceeds and about $1.1 billion in net proceeds; pro forma cash is about $3.4 billion.
OPUS-2 and OPUS-3 Phase 3 results are expected in the first half of 2027, with a BLA submission planned for the first half of 2028.
Design Therapeutics reported third quarter 2026 results on November 4, 2026, with a net loss of $20.3 million, up from $17.0 million a year earlier, as research and development and general and administrative expenses both rose. The company had no revenue in the figures provided, and cash, cash equivalents and investment securities were $208.6 million at September 30, 2026, down from $219.8 million at December 31, 2025, which matters to shareholders because it shows the company funding larger losses from its cash balance.
Q3 2026 net loss was $20.3 million, or $0.32 per share, versus $17.0 million, or $0.30 per share, in Q3 2025.
R&D expenses were $16.9 million in Q3 2026 versus $14.6 million a year earlier; G&A expenses were $5.3 million versus $4.7 million.
Cash and investment securities were $208.6 million at September 30, 2026, compared with $219.8 million at December 31, 2025.
The company expects a registrational plan update for DT-216P2 in Q4 2026 and 12-week RESTORE-FA data in Q1 2027.
Western Union reported third-quarter 2026 revenue of $1.0 billion, down 2% from the prior year, and GAAP earnings per share of $0.25, down from $0.43. Adjusted EPS was $0.42, down from $0.47, as lower revenue, a higher GAAP tax rate and $37.3 million of Beyond efficiency program costs weighed on results. The company also updated its full-year 2026 outlook, which assumes the pending Intermex acquisition closes on November 10, 2026, and the merger still awaits reinstatement of California regulatory approval.
Q3 2026 GAAP revenue was $1.0 billion, down 2%; adjusted revenue declined 1%
GAAP EPS was $0.25 versus $0.43 a year earlier; adjusted EPS was $0.42 versus $0.47
Full-year 2026 EPS outlook is $1.28 to $1.38; revenue outlook is 0% to 1% including Intermex and (2)% to (1)% excluding it
The Intermex merger remains subject to reinstatement of the California DFPI's approval and can be terminated if not completed by November 10, 2026
Kailera Therapeutics reported a third-quarter 2026 net loss of $95.7 million, up from $39.6 million in the same period of 2025, as research and development and general and administrative expenses rose sharply. The company reported cash, cash equivalents and marketable securities of $1,037.6 million as of September 30, 2026, which it expects to fund operations into mid-2028.
Q3 2026 R&D expenses were $84.7 million, up from $27.0 million a year earlier.
Q3 2026 general and administrative expenses were $21.7 million, up from $13.1 million.
Ribupatide oral global Phase 3 program is expected to begin in the first half of 2027, following an End-of-Phase 2 meeting with the U.S. FDA.
Cash of $1,037.6 million is expected to fund operations into mid-2028.
Mineralys Therapeutics reported a third-quarter 2026 net loss of $57.3 million, up from $36.9 million a year earlier, as general and administrative expenses rose to $37.4 million to prepare for commercial launch of lorundrostat. The company said its FDA review of lorundrostat has a PDUFA target date of December 22, 2026, and that its cash should fund operations into 2028. A director, Derek DiRocco, also plans to resign from the board effective December 31, 2026.
Net loss was $57.3 million, or $0.64 per share, versus $36.9 million, or $0.52 per share, a year earlier.
General and administrative expenses were $37.4 million, up from $9.7 million, driven by $15.4 million in higher professional fees and $11.4 million in higher personnel costs.
Cash, cash equivalents and investments were $624.7 million at September 30, 2026, versus $656.6 million at December 31, 2025.
Director Derek DiRocco will resign from the board effective December 31, 2026, and said the decision was not due to any disagreement with the company.
Traeger reported third-quarter fiscal 2026 revenue of $74.7 million, down 40.4% from a year earlier, and a net loss of $28.5 million. The company narrowed its full-year revenue and Adjusted EBITDA guidance ranges while keeping the midpoints unchanged, and it expects a return to revenue and Adjusted EBITDA growth in the fourth quarter.
Third-quarter revenue fell 40.4% to $74.7 million; grill revenue fell 48.1% to $39.7 million
Adjusted EBITDA was a loss of $3.3 million, compared with positive Adjusted EBITDA of $13.8 million a year earlier
FY26 revenue guidance narrowed to $440 million to $460 million from $435 million to $465 million; Adjusted EBITDA guidance narrowed to $59 million to $65 million from $57 million to $67 million
Cash and cash equivalents were $67.8 million at September 30, 2026, compared with $19.6 million at December 31, 2025
Net Lease Office Properties filed supplemental third-quarter 2026 financial information showing a net loss attributable to the company of $649,000, or $0.04 per share, on lease revenues of $5.9 million. The results included $6.5 million of real estate impairment charges, partly offset by a $5.5 million gain on property sales. In November 2026 the board declared a special cash distribution of $1.50 per share, about $22.2 million in total, payable December 1, 2026 to holders of record as of November 16, 2026.
Q3 2026 net loss attributable to the company was $649,000 ($0.04 per share); real estate impairment charges were $6.5 million.
AFFO attributable to the company was $3.0 million, or $0.20 per diluted share, for the quarter; FFO was $2.4 million, or $0.16 per share.
Special cash distribution of $1.50 per share, about $22.2 million, payable December 1, 2026 to shareholders of record as of November 16, 2026.
Occupancy was 68.9% at September 30, 2026, with 16 properties; cash and cash equivalents were $30.6 million.
Energy Recovery reported third-quarter 2026 results on November 4, 2026, with revenue of $11.2 million, down from $32.0 million a year earlier, and a net loss of $6.3 million, compared with net income of $3.9 million in the third quarter of 2025. The company attributed the decline in operating results primarily to lower revenue, which it linked to the war in Iran, and said its outlook for 2026 appears in a separate shareholder letter that is not part of this filing.
Q3 2026 revenue was $11.2 million, down 65% from $32.0 million in Q3 2025.
Net loss was $6.3 million, or $0.12 per diluted share, versus net income of $3.9 million, or $0.07 per diluted share, a year earlier.
Gross margin fell to 37.5% from 64.2%, and the loss from operations was $9.8 million.
Cash and investments totaled $85.6 million as of September 30, 2026.
Inseego reported third quarter 2026 results for its legacy business, with revenue of $33.3 million, down from $45.9 million a year earlier, and a GAAP net loss of $8.1 million compared with net income of $1.4 million in Q3 2025. The company completed its acquisition of Nokia's Fixed Wireless Access business on October 1, 2026, and guided fourth quarter revenue of $56 million to $65 million, which includes the acquired business for the first time.
Q3 2026 revenue was $33.3 million versus $45.9 million in Q3 2025; Adjusted EBITDA was negative $1.0 million.
GAAP net loss was $8.1 million in Q3 2026, compared with net income of $1.4 million in Q3 2025.
Nokia's FWA business acquisition was completed October 1, 2026, and its results will be consolidated beginning Q4 2026.
Q4 2026 guidance: revenue of $56 million to $65 million and Adjusted EBITDA of $0 million to $2 million, including $12 million to $14 million of Nokia support payments.
Lesaka reported first-quarter fiscal 2027 results for the quarter ended September 30, 2026, in a press release furnished under Item 2.02. Revenue fell 0.6% year on year in rand terms, net revenue rose 8%, group Adjusted EBITDA fell 17%, and adjusted earnings per share fell 26%. The company reaffirmed its FY2027 guidance, which includes the pending Bank Zero acquisition, subject to regulatory approval.
Q1 FY2027 revenue of ZAR 3.01 billion, down 0.6% year on year; net revenue of ZAR 1.58 billion, up 8%
Group Adjusted EBITDA of ZAR 220 million, down 17%; adjusted EPS of ZAR 0.72 versus ZAR 0.97 a year earlier
Net loss attributable to Lesaka of $4.2 million, compared with $4.7 million in Q1 FY2026
FY2027 guidance reaffirmed: adjusted EPS of ZAR 7.50 to ZAR 8.50; Q2 FY2027 adjusted EPS guidance of ZAR 1.00 to ZAR 1.40
Upland Software reported third quarter 2026 total revenue of $47.5 million, down 6% from a year earlier, and a GAAP net loss of $0.5 million, compared with $1.1 million a year earlier. It guided to full-year 2026 total revenue of $190.1 to $193.1 million, a 12% decline at the midpoint, and outlined a three-phase plan targeting an adjusted EBITDA margin of approximately 35% in the first half of 2028. For shareholders, the headline revenue, profit and guidance measures point lower, although the GAAP loss narrowed and the company repaid debt.
Q3 2026 total revenue was $47.5 million, down from $50.5 million; Adjusted EBITDA was $12.6 million, or 27% of revenue, versus $16.0 million, or 32%, a year earlier.
Full-year 2026 total revenue is expected at $190.1 to $193.1 million; Q4 2026 total revenue is expected at $44.7 to $47.7 million.
Term loan balance was $225.4 million at September 30, 2026, down from $238.5 million at December 31, 2025; cash was $28.9 million and the $30.0 million revolver was undrawn.
On July 31, 2026, Nasdaq notified the company it no longer meets the $15 million minimum market value of publicly held shares; the company has until January 27, 2027 to regain compliance.
HMH Holding reported third quarter 2026 revenue of $171.1 million, down 21% from a year earlier, and net income attributable to HMH of $5.0 million, compared with $16.2 million in the third quarter of 2025. Management said several equipment and upgrade opportunities shifted to later periods, while orders rose 12% year over year. The company also completed its $14.5 million acquisition of Deepwater Riser Services and is consolidating its U.S. Gulf riser operations in Houma, Louisiana.
Revenue of $171.1 million, down 21% from $217.2 million in Q3 2025 and substantially flat versus Q2 2026
Net income attributable to HMH of $5.0 million, versus $16.2 million in Q3 2025
Orders of $191 million, up 12% year over year and down 7% sequentially; book-to-bill of 1.12x
Adjusted EBITDA of $38.2 million, down 3% year over year and up 13% sequentially; no full-year guidance given
Niagen Bioscience reported third-quarter 2026 results with net sales of $27.2 million, down from $34.0 million a year earlier, and a net loss of $1.2 million, compared with net income of $4.6 million in the prior-year quarter. The company said 2026 is an investment year, expects operating expenses to rise, and expects its ingredient business to be lower than last year, which weighs on shareholders' near-term earnings outlook.
Q3 2026 net sales were $27.2 million, including $23.3 million from Tru Niagen, versus $34.0 million in Q3 2025.
Net loss was $1.2 million, or $(0.01) per share, versus net income of $4.6 million in Q3 2025.
Adjusted EBITDA, a non-GAAP measure, was $0.5 million, versus $6.4 million a year earlier.
Cash and cash equivalents were $69.5 million at September 30, 2026, up from $66.7 million at June 30, 2026.
MFA Financial reported a GAAP net loss to common stockholders of $(122.4) million, or $(1.19) per share, for the quarter ended September 30, 2026, compared with income of $0.36 per basic share in the same quarter of 2025. Distributable earnings, a non-GAAP measure, were $26.4 million, or $0.26 per share, and GAAP book value fell to $11.12 per common share, with a total economic return of (10.6)% for the quarter, which hurts shareholder value.
GAAP net loss to common stockholders of $(122.4) million, or $(1.19) per basic and diluted share, for Q3 2026
Distributable earnings of $26.4 million, or $0.26 per basic share, versus $21.1 million in Q3 2025
GAAP book value was $11.12 per common share at September 30, 2026; total economic return was (10.6)% for the quarter
Craig Knutson will retire as CEO effective June 30, 2027; Bryan Wulfsohn becomes CEO July 1, 2027
Aprea Therapeutics reported a third-quarter 2026 net loss of $4.8 million, or $(0.09) per share, up from $3.0 million, or $(0.47) per share, a year earlier, as research and development spending rose. The company had $37.8 million in cash and cash equivalents at September 30, 2026, and expects that cash to fund operations into the first quarter of 2028, while it expands its Phase 1 trial of APR-1051.
Q3 2026 operating loss was $5.2 million, compared with $3.1 million in Q3 2025; no grant revenue was recorded versus $1,848 a year earlier.
R&D expenses were $3.3 million, up from $1.6 million, mainly due to a $2.1 million increase for the ACESOT-1051 trial.
Cash and cash equivalents were $37.8 million at September 30, 2026, up from $14.6 million at December 31, 2025.
Interim ACESOT-1051 data will be presented as an oral presentation on November 20, 2026, at the ENA 2026 symposium in Barcelona.
Rand Capital reported third quarter 2026 results on November 4, 2026. Total investment income fell 17% from a year earlier to $1.3 million, mainly because certain portfolio investments were placed on non-accrual status, and net investment income dropped to $669,000, or $0.23 per share, from $0.33 per share. Net asset value per share was $17.36 at September 30, 2026, up slightly from $17.33 at June 30, 2026 but below $17.57 at December 31, 2025.
Total investment income was $1.3 million, down $268,000 or 17% from $1.6 million in the third quarter of 2025.
Net investment income was $669,000, or $0.23 per share, compared with $0.33 per share in the third quarter of 2025.
Net asset value per share was $17.36 at September 30, 2026, versus $17.33 at June 30, 2026 and $17.57 at December 31, 2025.
Cash and cash equivalents were $223,000 at quarter-end, and $5.0 million was outstanding on the line of credit.
MarineMax reported fiscal fourth-quarter revenue of $520.1 million, down from $552.2 million a year earlier, with a GAAP net loss of $13.0 million, or $0.59 per share, versus a $0.9 million loss a year earlier. Gross margin rose to 37.4%, but higher acquisition-related costs pushed SG&A up, and the company will not hold a call or give fiscal 2027 guidance because of its pending sale to Safe Harbor for $53.00 per share in cash.
Q4 revenue was $520.1 million versus $552.2 million, with lower boat sales partly offset by marinas and parts and service.
Q4 net loss attributable to MarineMax was $13.0 million, or $0.59 per share; adjusted net loss was $1.8 million, or $0.08 per share.
Full-year revenue was $2.2 billion; full-year adjusted diluted earnings per share were $0.58, versus $0.42 in fiscal 2025.
Safe Harbor will acquire MarineMax for $53.00 per share in cash, an enterprise value of about $1.5 billion, expected to close by the end of calendar 2026.
Natural Resource Partners L.P. reported third quarter 2026 net income of $26.5 million, down from $30.9 million a year earlier, and total revenues and other income of $44.8 million, down from $49.9 million. The partnership declared a third quarter distribution of $2.34 per common unit, up from $0.75 per unit paid for the second quarter of 2026, and said it fully repaid its credit facility balance during the quarter.
Q3 2026 net income $26.5 million vs. $30.9 million in Q3 2025; basic net income per common unit $1.96 vs. $2.31
Free cash flow of $44.8 million in Q3 2026; free cash flow available for distributions of $31.7 million
Third quarter distribution of $2.34 per common unit, payable November 24, 2026, to holders of record on November 17, 2026
Remaining $14.3 million of debt matures in December 2026; available liquidity of $251.7 million at September 30, 2026
Lifecore Biomedical reported third-quarter 2026 revenue of $25.3 million, down 18.6% from $31.1 million a year earlier, and a net loss of $40.1 million, or $1.08 per diluted share, compared with a $10.0 million loss, or $0.29 per share, in the prior-year quarter. The filing attributes much of the larger loss to a $31.3 million change in fair value of a related-party debt derivative liability, while adjusted EBITDA rose to $4.0 million, which matters to shareholders because revenue and reported profit both moved against them.
Q3 2026 revenue was $25.3 million vs. $31.1 million; nine-month revenue was $82.7 million vs. $105.7 million.
Q3 2026 net loss was $40.1 million, or $1.08 per diluted share, vs. a $10.0 million loss, or $0.29 per share, a year earlier.
Q3 change in fair value of debt derivative liability, related party, was a $31.3 million charge; Q3 adjusted EBITDA was $4.0 million vs. $3.1 million.
Liquidity was approximately $38.0 million at September 30, 2026, including $23.0 million in cash and $15.0 million of revolving credit availability.
Criteo reported third-quarter 2026 revenue of $416 million, down 11% from $470 million a year earlier, and net income of $6 million, or $0.11 per diluted share, versus $40 million, or $0.70 per share. The company kept its full-year 2026 Contribution ex-TAC outlook of down 12% to 10% at constant currency and gave fourth-quarter guidance that reflects previously communicated Retail Media scope changes, so shareholders face continued pressure on revenue and profit.
Q3 2026 revenue was $416 million, down 11% from $470 million; gross profit was $208 million, down 19%.
Net income was $6 million, or $0.11 per diluted share, compared with $40 million, or $0.70 per share, in Q3 2025.
Q4 2026 guidance: Contribution ex-TAC of $292 million to $298 million and Adjusted EBITDA of $105 million to $111 million.
Criteo spent $65 million on share repurchases in the first nine months of 2026, and expects its legal domicile transfer to the United States to be completed on January 1, 2027, subject to shareholder approval.
Odyssey Therapeutics reported third quarter 2026 results on November 4, 2026, with a GAAP net loss of $53.1 million, up from $35.5 million a year earlier. Research and development expenses rose to $42.1 million from $26.3 million, and the company said it had $387 million in cash, cash equivalents and marketable securities, expected to fund operations into the second half of 2028.
GAAP net loss of $53.1 million for the quarter ended September 30, 2026, versus $35.5 million a year earlier; adjusted net loss (non-GAAP) was $41.9 million
R&D expenses of $42.1 million versus $26.3 million, mainly higher external costs for clinical and preclinical programs; G&A expenses of $11.2 million versus $10.2 million
Cash, cash equivalents and marketable securities of $387 million as of September 30, 2026, expected to fund operations into the second half of 2028
Anthony Opipari, M.D., Ph.D., appointed chief medical officer and Laura Hare appointed chief people officer
Perrigo reported third-quarter 2026 net sales of $989 million, down 5.2% from a year earlier, and a GAAP net loss of $27.5 million. The company cut its Core full-year 2026 adjusted EPS outlook to $2.15 to $2.35 from $2.25 to $2.55, citing softer consumer demand, retailer inventory positioning and Europe. It also agreed to sell its Infant Formula business for up to $175 million and expects a $275 million to $375 million impairment loss in the fourth quarter.
All In adjusted diluted EPS was $0.60 versus $0.80 a year earlier, down 25.0%; Core adjusted EPS was $0.61, down 9.0%.
Full-year 2026 Core adjusted EPS outlook is $2.15 to $2.35, down from $2.25 to $2.55; All In outlook is $2.25 to $2.45, up from $2.00 to $2.30 and reflects the Infant Formula divestiture.
Infant Formula sale carries $40 million in upfront cash at closing plus up to $135 million contingent on net sales milestones through 2030.
Expected impairment loss of $275 million to $375 million to be recognized in the fourth quarter of 2026.
Blackstone Secured Lending Fund (BXSL) reported third quarter 2026 net investment income of $158 million, or $0.68 per share, down from $0.75 in the prior quarter and $0.82 in the third quarter of 2025. Net income was $117 million, or $0.50 per share, and net asset value fell to $25.25 per share from $25.53 at June 30, 2026. The Board declared a fourth quarter dividend of $0.77 per share, which is above the quarter's net investment income per share.
Net investment income of $0.68 per share, versus $0.75 in 2Q 2026 and $0.82 in 3Q 2025
Net income of $117 million, or $0.50 per share, versus $0.04 per share in 2Q 2026 and $0.57 in 3Q 2025
Net asset value of $25.25 per share at September 30, 2026, versus $27.15 a year earlier
Fourth quarter 2026 dividend of $0.77 per share, record date December 31, 2026, payable on or about January 22, 2027
SLR Investment Corp. reported net investment income of $17.8 million, or $0.33 per share, for the quarter ended September 30, 2026, down from $21.6 million, or $0.40 per share, a year earlier. Net asset value fell to $17.83 per share from $18.00 at June 30, 2026, and the board declared a $0.31 per share quarterly distribution, which the company said its net investment income covered.
Net investment income was $17.8 million, or $0.33 per share, versus $21.6 million, or $0.40 per share, a year earlier; flat sequentially per management.
Net increase in net assets from operations was $7.6 million, or $0.14 per share, versus $23.3 million, or $0.43 per share, a year earlier.
Net asset value was $17.83 per share at September 30, 2026, compared with $18.00 at June 30, 2026.
Quarterly distribution of $0.31 per share is payable December 28, 2026, to holders of record as of December 14, 2026.
Primoris reported third-quarter 2026 revenue of $2.0 billion, down 10.4% from a year earlier, and net income of $51.3 million, or $0.95 per diluted share, versus $1.73 in the third quarter of 2025. The decline was mainly due to lower renewables activity in the Energy segment, and the company updated its full-year 2026 guidance while also declaring a dividend and authorizing a $250 million share purchase program.
Q3 2026 revenue was $2.0 billion, down 10.4%; Energy segment revenue fell 17.6%.
Diluted EPS was $0.95 versus $1.73; adjusted diluted EPS was $1.20 versus $1.88.
Full-year 2026 diluted EPS guidance is $1.20 to $1.35; adjusted EPS guidance is $2.10 to $2.25.
Board declared a $0.08 per share dividend payable about January 15, 2027, and authorized a $250 million buyback with no expiration date.
XMax Inc. released unaudited preliminary third-quarter 2026 results showing net sales of about $6.42 million, down from $9.76 million a year earlier, and an expected net loss of $12.10 million to $13.10 million, driven mainly by a non-cash unrealized loss. The numbers are not final: closing procedures are incomplete, the auditor has not reviewed them, and the complete results are due in a Form 10-Q by November 16, 2026.
Q3 2026 net sales of about $6.42 million versus $9.76 million in Q3 2025; gross margin of about 13.9% versus 10.1%
Expected Q3 2026 net loss of $12.10 million to $13.10 million, primarily a non-cash unrealized loss
Nine-month net sales of about $10.94 million versus $14.95 million; expected nine-month net income of $19.50 million to $20.50 million, mainly a non-cash unrealized gain
Board approved a share repurchase program of up to $30 million; final Form 10-Q expected on or before November 16, 2026
InMed Pharmaceuticals reported a first-quarter fiscal 2027 net loss of $2.3 million for the quarter ended September 30, 2026, up from $1.7 million a year earlier, and cash fell to $1.0 million from $2.2 million at June 30, 2026. The company said its cash is expected to fund operations into mid-November, and it reported shareholders' equity of negative $1.2 million, below Nasdaq's $2.5 million minimum, with a compliance deadline of March 15, 2027. Shareholders vote on the proposed Mentari merger at a meeting on November 4, 2026.
Net loss of $2.3 million, or $0.42 per share, for the quarter ended September 30, 2026, compared with a net loss of $1.7 million, or $0.44 per share, a year earlier
Cash and cash equivalents of $1.0 million at September 30, 2026, versus $2.2 million at June 30, 2026; cash expected to fund operations into mid-November
Shareholders' equity was negative $1.2 million at September 30, 2026; Nasdaq set a March 15, 2027 deadline to regain compliance with its $2.5 million minimum
Annual general and special meeting on November 4, 2026, to consider proposals needed to complete the Mentari merger, which is expected to close in the fourth quarter of calendar 2026
Mosaic reported a third-quarter 2026 net loss of $72 million, or $0.23 per diluted share, compared with net income of $411 million, or $1.29 per share, a year earlier. Net sales fell to $3.1 billion from $3.5 billion, and adjusted EBITDA dropped to $324 million from $806 million, mainly on lower sales volumes and higher raw material costs in phosphate and Mosaic Fertilizantes. For shareholders, the results show a much weaker quarter, with the company citing expected improvement in fourth-quarter free cash flow.
Q3 2026 net loss of $72 million versus net income of $411 million in Q3 2025; diluted loss per share of $0.23 versus earnings of $1.29
Net sales of $3.1 billion versus $3.5 billion a year earlier; operating loss of $97 million
Phosphate operating loss of $194 million; Potash operating earnings of $189 million, down from $229 million
Full-year 2026 potash production now expected to be 8.6 million tonnes; fourth-quarter potash sales volumes expected at 2.3 to 2.6 million tonnes
Comscore reported third-quarter 2026 revenue of $76.2 million, down 14.3% from $88.9 million a year earlier, partly due to the May 2026 divestiture of its Movies business. The company posted a net loss of $65.5 million, compared with net income of $0.5 million, mainly due to a non-cash goodwill impairment charge of $57.3 million and $5.5 million in restructuring costs. Comscore reaffirmed its full-year 2026 revenue outlook of $315 million to $325 million, but the filing shows lower revenue and a sharp swing to a loss for shareholders.
Q3 2026 revenue was $76.2 million, versus $88.9 million in Q3 2025 and $79.4 million on a pro forma basis excluding Movies revenue of $9.5 million
Net loss was $65.5 million, or $(4.26) per share, including a $57.3 million goodwill impairment and $5.5 million in restructuring costs
Adjusted EBITDA was $5.8 million, down from $11.0 million, with the margin falling to 7.6% from 12.4%
Cash, cash equivalents and restricted cash totaled $19.5 million as of September 30, 2026; full-year 2026 revenue outlook of $315 million to $325 million was reaffirmed
Aquestive reported third-quarter 2026 revenue of $7.6 million, down 41% from $12.8 million a year earlier, mainly due to the timing of Suboxone product orders. Its net loss widened to $16.5 million, or $0.13 per share, from $15.4 million, or $0.14 per share, while the company said its full-year 2026 guidance is unchanged. Shareholders face a weaker quarter, with the FDA decision on Anaphylm, due March 16, 2027, still ahead.
Q3 2026 total revenue was $7.6 million, down from $12.8 million in Q3 2025.
Net loss was $16.5 million, or $0.13 per share, versus $15.4 million, or $0.14 per share, a year earlier.
Non-GAAP adjusted EBITDA loss was $12.2 million, compared with $8.6 million in Q3 2025.
Full-year 2026 total revenue guidance of $46 million to $50 million was unchanged; cash and cash equivalents were $90.3 million at September 30, 2026.
Redwood Trust reported a third-quarter 2026 GAAP net loss related to common stockholders of $47.3 million, or $0.39 per basic share, compared with $2.9 million, or $0.03 per share, in the second quarter. GAAP book value per common share fell 4.9% to $6.56, and the company announced a planned transition to a C-corporation in 2027, which it expects to add $0.73 to $0.77 per share to GAAP book value in the fourth quarter of 2026.
Net loss related to common stockholders was $47.3 million ($0.39 per basic share) for Q3 2026, versus $2.9 million ($0.03 per share) in Q2 2026.
Non-GAAP Earnings Available for Distribution was $(0.02) per share, down from $0.15 in Q2 2026; Core Segments EAD was $0.18 per share, down from $0.25.
Unrestricted cash and cash equivalents were $201 million at September 30, 2026, and the non-GAAP recourse leverage ratio rose to 5.2x from 5.0x.
The company plans to transition to a C-corporation in 2027, with an expected initial increase of $0.73 to $0.77 per share in GAAP book value in Q4 2026.
Fortune Brands reported third quarter 2026 net sales of $1.1 billion, down 3.1% from a year earlier, and GAAP diluted EPS of $0.42 after a $73.8 million asset impairment charge. EPS before charges and gains rose 4.6% to $1.14, helped by a $0.28 net tax benefit and $0.14 of net tariff refunds. The company cut its full-year 2026 EPS before charges and gains guidance to $3.20 to $3.30, from a prior midpoint of $3.37, as it sells Fiberon, exits its China business and reduces its EMEA footprint.
Q3 2026 net sales were $1.1 billion, down 3.1%; GAAP operating income was $60.4 million, down 52.0%.
Full-year 2026 EPS before charges and gains guidance is $3.20 to $3.30, versus a prior midpoint of $3.37.
Full-year 2026 net sales guidance is $4,205 million to $4,275 million.
The company entered a purchase agreement to sell Fiberon, exits China commercial operations by Q3 2027, and expects $70 million of annualized SG&A savings by Q1 2027.
Neostellar Capital reported a $21.2 million net decrease in net assets from operations for the quarter ended September 30, 2026, or $0.80 per share, compared with a $7.4 million increase a year earlier. The quarter included a $4.0 million net investment loss, a $7.7 million net realized loss and $9.4 million of net unrealized depreciation, and net asset value fell to $12.64 per share from $13.44 at June 30, 2026. Shareholders face a lower per-share asset value for the quarter, though nine-month net assets from operations still rose $115.8 million.
Net decrease in net assets from operations of $21.2 million, or $0.80 per share, for the quarter ended September 30, 2026, versus a $7.4 million increase, or $0.30 per share, a year earlier.
Net asset value per share was $12.64 at September 30, 2026, down from $13.44 at June 30, 2026 and up from $9.23 at September 30, 2025.
Nine-month net increase in net assets from operations was $115.8 million, or $4.46 per basic share.
Board extended the share repurchase program to the earlier of October 31, 2027 or repurchase of $64.3 million, with approximately $25.0 million remaining.
QuidelOrtho reported third-quarter 2026 revenue of $619 million, down 12% from the prior year, and a GAAP net loss of $54 million, or $0.78 per diluted share. The company lowered its top-end 2026 guidance for adjusted diluted EPS to $0.65 to $0.70 from $0.65 to $0.90, and launched a restructuring program it expects to save over $80 million a year in 2027, with $30 million to $35 million in one-time charges in the fourth quarter of 2026.
Q3 2026 revenue $619 million, down 12%; Point of Care revenue fell 27% on a softer respiratory season
Q3 GAAP net loss $54 million ($0.78 per share); adjusted diluted EPS $0.31
2026 guidance: revenue $2.52 to $2.54 billion; adjusted EBITDA $540 to $545 million; adjusted EPS $0.65 to $0.70 (previously $0.65 to $0.90)
Effective November 9, 2026, Chief Operations Officer Phil McLellan's role is eliminated; Jonathan Siegrist and Bryan Hanson named heads of the two new businesses
Contineum Therapeutics reported third-quarter 2026 results on November 3, 2026. The net loss widened to $18.7 million from $12.8 million a year earlier, driven by higher research and development and general and administrative expenses. The company reported $244.5 million in cash, cash equivalents and marketable securities as of September 30, 2026, and said this is sufficient to fund planned operations through mid-2029.
Net loss for the three months ended September 30, 2026 was $18.7 million, compared with $12.8 million in the third quarter of 2025.
Research and development expenses were $16.0 million, up 45 percent from a year earlier, mainly due to the PIPE-791 IPF program and employee-related costs.
General and administrative expenses were $5.0 million, up 26 percent, mainly due to higher stock-based compensation and employee-related costs.
Cash, cash equivalents and marketable securities were $244.5 million at September 30, 2026.
Flux Power reported fiscal first-quarter 2027 results for the quarter ended September 30, 2026, with revenue of $6.8 million, down from $13.2 million a year earlier and $8.2 million in the prior quarter. The net loss was $3.2 million, or $(0.15) per share, compared with a $2.6 million loss a year earlier, and the company said it is evaluating financing alternatives while cash stood at $0.4 million.
Revenue was $6.8 million, versus $13.2 million a year ago and $8.2 million in the prior quarter; gross margin was 24.8% versus 28.6% a year ago.
Net loss was $3.2 million, or $(0.15) per share, versus $2.6 million, or $(0.15) per share, a year ago.
Operating expenses fell to $4.6 million from $5.9 million a year ago, which the company attributed to prior headcount reductions.
The company guided fiscal second-quarter 2027 revenue to $7 million to $8 million and reported cash of $0.4 million as of September 30, 2026.
Finance of America reported a third-quarter 2026 net loss of $110 million, or $5.24 per basic share, mainly due to $125 million in non-cash fair value changes. Funded volume rose 24% to $748 million, but total revenues were negative $58 million, compared with $81 million a year earlier, and adjusted EPS fell to $0.28 from $1.33.
Net loss of $110 million, or $5.24 per basic share, for the quarter ended September 30, 2026, versus basic EPS of $0.10 in the prior quarter
Total revenues were negative $58 million, compared with $81 million in Q3 2025
Funded volume rose 24% year over year to $748 million; adjusted EPS was $0.28 versus $1.33 a year earlier
Cash and cash equivalents rose $33 million to $118 million; the company expects to complete a $60 million senior secured notes paydown in November 2026
Angi reported third-quarter 2026 revenue of $242.0 million, down 9% from $265.6 million a year earlier, with net earnings of $1.3 million, or $0.03 per diluted share, versus $10.6 million, or $0.23, in Q3 2025. The company also said it will cut about 300 roles, with expected annual run-rate savings of $50.0 million to $60.0 million and restructuring charges of $18.0 million to $30.0 million, which matter to shareholders because they affect near-term profitability.
Q3 2026 revenue $242.0 million, down 9% year over year; operating income $15.5 million, down from $21.8 million
Adjusted EBITDA rose 6% to $42.2 million; free cash flow was $14.4 million versus $4.9 million in Q3 2025
Workforce reduction of about 300 roles announced November 3, 2026, with $50.0 million to $60.0 million expected annual run-rate savings
Year-to-date operating loss of $227.7 million includes $235.2 million of goodwill and intangible impairments recorded in Q2 2026
Sixth Street Specialty Lending reported third quarter 2026 GAAP net investment income of $0.44 per share and net income of $0.36 per share, down from $0.54 and $0.47 a year earlier. Investment income fell to $99.0 million from $109.4 million, which the company attributed mainly to lower reference rates. The board also declared a fourth quarter base dividend of $0.42 per share, below the $0.46 base dividend shown for the prior comparison period, plus a $0.01 supplemental dividend.
Net investment income per share was $0.44 versus $0.54 in the third quarter of 2025; net income per share was $0.36 versus $0.47.
Investment income was $99.0 million versus $109.4 million a year earlier, mainly due to lower reference rates.
Net asset value per share was $16.19 at September 30, 2026, versus $17.14 at September 30, 2025.
Fourth quarter base dividend of $0.42 per share is payable December 31, 2026 to holders of record as of December 15, 2026; a $0.01 supplemental dividend is payable December 21, 2026 to holders of record as of November 30, 2026.
RxSight reported third quarter 2026 results for the period ended September 30, 2026, with total revenue down 19% from the prior-year quarter, primarily reflecting ongoing competitive pressures. The net loss widened to $16.2 million, or $0.39 per share, from $9.8 million, or $0.24 per share, a year earlier, and gross margin fell to 73.6% from 79.9%. Shareholders also get a company that ended the quarter with $254.7 million in cash and short-term investments, including $60 million received in connection with the Alcon collaboration.
Third quarter total revenue was $24.6 million, down 19% from $30.3 million a year earlier; the filing cites ongoing competitive pressures.
Net loss was $16.2 million, or $0.39 per share, versus $9.8 million, or $0.24 per share, in the third quarter of 2025.
Gross margin was 73.6%, compared with 79.9%, reflecting higher inventory reserves and higher inventory costs.
Cash, cash equivalents and short-term investments totaled $254.7 million as of September 30, 2026; the company also appointed Taryn Conway as Chief Commercial Officer.
Skyworks reported fiscal fourth-quarter 2026 results for the period ended October 2, 2026, with revenue of $1,045.7 million, down from $1,100.2 million a year earlier, and GAAP diluted EPS of $0.15 versus $0.94. The company completed its Qorvo combination after the quarter ended, and its December-quarter revenue outlook of $1.80 billion to $1.90 billion, with non-GAAP EPS of $1.25 at the midpoint, is the first guidance for the combined company. Shareholders face lower reported profit and a larger share count and interest cost ahead, with the company targeting $500 million or more in annual cost synergies within 24 to 36 months of close.
Q4 revenue $1,045.7 million vs $1,100.2 million a year earlier; non-GAAP diluted EPS $1.28 vs $1.76
Fiscal 2026 revenue $3.96 billion vs $4.09 billion; GAAP diluted EPS $1.14 vs $3.08
December-quarter revenue outlook $1.80 billion to $1.90 billion; non-GAAP EPS of $1.25 at midpoint on about 241 million diluted shares
Restructuring, impairment and other charges of $82.1 million in the fourth quarter
Avis Budget Group reported third quarter 2026 revenue of $3.4 billion, down 2% from a year earlier, and net income attributable to the company of $183 million, down 49%. Adjusted EBITDA fell 8% to $513 million, and diluted earnings per share were $5.15 versus $10.11 a year earlier, though the company said Americas vehicle utilization hit a third-quarter record.
Q3 revenue $3.4 billion ($3,436 million) vs. $3,519 million in Q3 2025; Adjusted EBITDA $513 million vs. $559 million
Diluted EPS $5.15 vs. $10.11 a year earlier; net income attributable to the company $183 million vs. $359 million
Total Company vehicle utilization 74.0%, up 2.0 points; Americas utilization 74.1%, both third-quarter record highs
Received $650 million from Pentwater Capital Management settlement on October 5, to be recognized in Q4; redeeming remaining $350 million of 5.750% Senior Notes due 2027
Gladstone Commercial reported third-quarter 2026 results with total operating revenue of $42.4 million, down 3.6% from the prior quarter, and a net loss of $2.1 million, compared with net income of $8.3 million in the second quarter. Core FFO fell 7.8% to $16.9 million, or $0.35 per share, which matters to shareholders because the quarter absorbed a $6.5 million impairment charge on one property and the company's cash distribution of $0.30 per share was unchanged.
Total operating revenue was $42.4 million for the quarter ended September 30, 2026, down $1.6 million from $44.0 million in the quarter ended June 30, 2026.
Net loss was $2.1 million, or a loss of $0.11 per share attributable to common stockholders, compared with net income available to common stockholders of $5.1 million, or $0.11 per share, in the prior quarter.
Core FFO was $16.9 million, or $0.35 per share, down 7.8% from the prior quarter, which the company attributed to higher property expenses, higher interest expense from the SOFR rate increase, and a lease termination fee recognized in the p
Cash dividends declared were $0.30 per common share for the quarter, unchanged from the prior quarter.
Spyre Therapeutics reported a third-quarter 2026 net loss of $96.1 million, up from $11.2 million a year earlier, as research and development expenses nearly doubled. The company also reported mixed trial results, with positive induction data for SPY003 in IBD but no plan to advance SPY072 in rheumatic diseases, and said its pro forma cash runway extends into the second half of 2029.
Net loss was $96.1 million for Q3 2026 versus $11.2 million for Q3 2025; net loss per common share was $(0.94) versus $(0.15).
R&D expenses rose to $89.2 million from $45.2 million, driven mainly by higher manufacturing costs and clinical trial expenses.
Prior-year other income included changes in the fair value of the CVR liability; Q3 2026 total other income was $9.6 million versus $45.7 million.
Pro forma cash, cash equivalents and marketable securities were $1,467.9 million as of September 30, 2026, including $378.0 million in net proceeds from an October 2026 public offering.
Key Tronic reported a first-quarter fiscal 2027 net loss of $7.5 million, or $0.69 per share, compared with a net loss of $2.3 million, or $0.21 per share, a year earlier. Revenue was roughly flat, while gross margin fell to 2.5% from 8.4%, and the company said supply chain financing constraints delayed about $18 million of shipments. The company will not issue revenue or earnings guidance for the second quarter, though it reported backlog of $245.9 million, up 76%.
Revenue was $98.7 million, compared with $98.8 million a year earlier.
Gross margin was 2.5%, compared with 8.4%; adjusted gross margin was 4.2%, compared with 9.6%.
Net loss was $7.5 million, or $0.69 per share; adjusted net loss was $7.9 million, or $0.72 per diluted share.
Backlog was $245.9 million, up 76%; the company will not provide second-quarter guidance and says its financial data is preliminary pending auditor review.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.